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9ABSTRACT
Markedly reduced levels of dopamine (DA) in the basal ganglia of the brain, manifest-
ing clinically as rest tremor, muscular rigidity, and slowness/absence of movement, are 
characteristic of Parkinson’s disease (PD). As yet, there is no curative treatment. Among 
the symptomatic therapies available, oral replacement of DA by its metabolic pre-cursor 
L-dopa is the most effective. Despite its unsurpassed effi cacy, however, L-dopa has sig-
nifi cant disadvantages: Its chronic use is associated with motor response complications, 
e.g., progressive shortening of the duration of drug effect (“wearing-off”), and abnormal 
involuntary movements (dyskinesia); in addition, extensive peripheral metabolism of L-
dopa results in its short half-life, low bioavailability, and reduced effi cacy.
In the periphery, oral L-dopa is metabolized mainly by two enzymes: aromatic amino 
acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT). Inhibitors of pe-
ripheral AAAD, either benserazide or carbidopa, form an integral part of modern L-dopa 
therapy. They markedly improve L-dopa bioavailability, although its half-life – and there-
fore its duration of effect in advanced PD – is not signifi cantly altered.
Some nitrocatechol-structured compounds are highly selective, reversible, and orally 
active inhibitors of COMT. Entacapone, as one example, has all these properties. It im-
proves the pharmacokinetics of L-dopa by increasing its bioavailability and plasma half-
life. Entacapone extends the duration of clinical response to each L-dopa dose in patients 
with advanced PD.
COMT is an important catecholamine-metabolizing enzyme, ubiquitously present in 
practically all human tissues. It inactivates both endogenous (e.g., noradrenaline, adrena-
line, DA) and exogenous catechol-structured compounds, therefore participating in the 
regulation of the effects of vaso- and neuroactive catechols both at the synaptic level 
(sympathetic nervous system) and in the circulation. Therapeutic reduction in COMT activ-
ity in PD could theoretically lead to adverse cardiovascular reactions, such as hypertension 
and arrhythmia, especially in circumstances of enhanced sympathetic activity (physical 
exercise). In addition, patients with PD may be particularly vulnerable to such effects be-
cause of the cardiovascular autonomic dysfunction prevalent in these patients, and  their 
use of other drugs that intervene in catecholamine metabolism, such as the monoamine 
oxidase B (MAO-B) inhibitor, selegiline. Co-administration of entacapone and selegiline 
may also lead to pharmacodynamic interactions in the central nervous system, either ben-
efi cial (improved L-dopa effi cacy) or harmful (increased dyskinesia, reduced sleep).
We investigated the effects of entacapone (in 3–5 daily doses of 200 mg each for 
1–2 weeks), administered either with or without selegiline (10 mg o.d.), on several safety 
(blood pressure, heart rate, ambulatory ECG, plasma catecholamine levels, cardiovascular 
autonomic function, cardiorespiratory exercise responses, adverse events, and dyskinesia) 
and effi cacy (clinical motor disability, L-dopa pharmacokinetics, daily L-dopa dosage) pa-
rameters in L-dopa-treated PD patients. A total of 39 patients took part in three double-
blind placebo-controlled, crossover studies. Patients had mild to moderate PD, both with 
(I–IV) and without (III, IV) fl uctuations in motor response. In two of the studies (I, II), the 
cardiovascular, clinical, and biochemical responses were investigated during an L-dopa 
test, in which the outcome parameters were repeatedly assessed for 6 hours, fi rst after
L-dopa only (control), and then after a 2-week treatment with the study drugs (entaca-
pone vs. entacapone + selegiline in I; entacapone vs. selegiline vs. entacapone + selegiline 
in II). The third study included assessment of standard cardiovascular refl ex tests (III) and 
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spiroergometric exercise testing (IV), fi rst after overnight drug withdrawal (control), and 
then after a 1-week treatment with entacapone and selegiline as adjuncts to L-dopa. Am-
bulatory ECG recordings (Holter) were incorporated in two of the studies (II, third study: 
unpublished results).
The parameters of cardiovascular function (blood pressure, heart rate, ambulatory 
ECG, cardiovascular autonomics, cardiorespiratory exercise responses) remained unaf-
fected by repeated administration of entacapone, irrespective of selegiline (I–IV). Neither 
entacapone nor selegiline altered the resting/exercise levels of circulating catecholamines, 
despite signifi cant changes in their metabolic profi le (I, IV).
Entacapone and selegiline, either alone or combined, improved clinical response to 
L-dopa (I, II). In one of the studies, this improvement was more pronounced during their 
co-administration than during entacapone alone (I). In the other study, entacapone, sel-
egiline, and their combination caused a similar improvement in L-dopa clinical response; 
dyskinesias were signifi cantly increased only after their co-administration (II). Entacapone 
signifi cantly enhanced L-dopa bioavailability. Although selegiline had no effect on L-dopa 
plasma levels, it caused distinct changes in its metabolic profi le (I). Entacapone had no 
effect on either work capacity or work effi ciency in patients treated with L-dopa and sel-
egiline (IV). Entacapone, both with and without selegiline, was generally well tolerated.
Based on the results from these formal studies, the concomitant use of entacapone 
with selegiline seems to be safe in L-dopa-treated PD patients, also in conditions of maxi-
mal physical effort. This is in line with the experience gathered from larger phase III 
studies, as well as with the general safety profi le of the drug. Entacapone had no effect 
on cardiovascular autonomic regulation. Concomitant administration of entacapone and 
selegiline may improve clinical effi cacy in some patients but may also lead to increased 
dyskinesia and unwanted adverse reactions, e.g., dizziness, reduced sleep, and nausea. 
Dopaminergic adverse reactions can be generally controlled by reductions in daily L-dopa 
dosage.
Keywords: Parkinson’s disease, COMT, entacapone, MAO-B, selegiline, hemodynamics, 
autonomic nervous system, catecholamines, exercise
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1. INTRODUCTION
The cardinal clinical features of Parkinson’s disease (PD) are poverty/loss of spontaneous 
and volitional movements (hypokinesia), rest tremor, muscular rigidity, and impairment in 
maintenance of both balance and posture. PD occurs sporadically, and generally in late 
life, with an average age of onset of about 60 years. Finland has approximately 750 new 
cases of PD each year, with the estimated total number of patients around 10 000.
A progressive decline in motor function generally occurs in PD, with many non-motor 
manifestations (autonomic, cognitive, sensory) possible. Eventually, signifi cant disability 
ensues in the majority of patients.
The most characteristic brain lesion in PD is the degeneration of pigmented neurons 
in the dense part of the substantia nigra (SN). These neurons project to the striatum – a 
key input station of the basal ganglia motor circuits – where they control neuronal fi ring 
through tonic release of the dopamine (DA) neurotransmitter. The motor manifestations 
of PD may be mainly due to the degeneration of nigrostriatal dopaminergic projections 
and the resulting defi ciency in striatal DA.
The causes of PD remain unknown. No defi nite environmental risk factors have been 
established, although several putative ones have been suggested. Recent discoveries in 
genetics have provided much insight into the pathogenesis of PD. Several distinct, al-
though rare, forms of genetically determined parkinsonism have been identifi ed. Defects 
in certain pathways of protein degradation, oxidative stress, and mitochondrial energy 
failure have all been implicated as possible mechanisms of nigral cell damage. The etiol-
ogy of sporadic PD is likely to be heterogeneous, i.e., consisting of a complex interplay of 
genetic and environmental factors.
In the 1960s, it emerged that L-dopa, a pre-cursor of DA, can cause a dramatic im-
provement in parkinsonian motor symptoms (1). L-dopa is orally active and can penetrate 
the blood-brain-barrier (BBB). It is thought that in the brain, exogenous L-dopa is con-
verted to DA, thereby partially restoring the functional dopaminergic defi ciency within 
the striatum.
Although initially highly effective, chronic use of L-dopa was soon observed to cor-
relate with signifi cant clinical problems (2). One is the deterioration of motor effect in a 
few hours after drug intake. This “wearing off” or “end-of-dose deterioration” has been 
reported to occur in up to half of the patients after fi ve years of therapy (3). Other more 
complex and enigmatic motor complications such as “random-off,” “freezing,” and in-
voluntary movements (dyskinesia) may also appear.
Other symptomatic drug therapies available are DA agonists with direct action on stri-
atal DA receptors, amantadine, and inhibitors of monoamine oxidase B (MAO-B), which 
reduce the metabolism of DA in the brain. These drugs have some distinct advantages, 
but generally are clearly less effi cacious than L-dopa.
Major shortcomings of L-dopa are rapid peripheral metabolism and a short half-life. 
Early on, inhibitors of peripheral aromatic amino acid decarboxylase (AAAD) – also called 
dopa decarboxylase (DDC) – were incorporated into L-dopa therapy. These markedly re-
duce the peripheral conversion of L-dopa to DA, thus resulting in a major improvement in 
both effi cacy and tolerability. Later, controlled release (CR) formulations of L-dopa/DDC 
inhibitor were developed to improve the duration of action of the drug, especially in pa-
tients with end-of-dose fl uctuations. One quite recent strategy for improving the effi cacy 
of L-dopa has been introduction of inhibitors of catechol-O-methyltransferase (COMT).
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The enzymatic inactivation of catecholamines through O-methylation by COMT was 
fi rst described by Axelrod (4–6). Clinical experience with early COMT inhibitors was dis-
appointing: These compounds showed poor effi cacy and were rather toxic (7). In the 
1980s, however, a class of highly potent, selective, and orally active inhibitors of COMT 
was developed (8), including entacapone and tolcapone. These drugs reduce the periph-
eral metabolism of L-dopa, thereby increasing its half-life and availability for entry into 
the brain (9). Large, prospective, double-blind clinical trials have shown both entacapone 
and tolcapone to extend the duration of effect of a single L-dopa dose and to increase 
the amount of time with motor benefi t from L-dopa in PD patients with end-of-dose 
fl uctuations (10–13). Nowadays, entacapone is the only COMT inhibitor widely used in 
clinical practice, whereas use of tolcapone has been restricted due to its potential for liver 
toxicity.
A signifi cant amount of COMT activity exists in practically all tissues (14, 15); this en-
zyme is important in terminating the actions of biologically active – especially circulating 
– catecholamines of both endo- and exogenous origin. It is conceivable that inhibition of 
COMT may lead to an increase in concentrations and biological effects (e.g., arrhythmia 
and hypertension) of its catechol substrates noradrenaline (NA) and adrenaline, espe-
cially under conditions of enhanced release (exercise). It therefore seemed prudent to 
investigate whether the use of entacapone is associated with any signifi cant effects on 
plasma catecholamine levels, hemodynamics or cardiovascular autonomic function. No 
such changes have been reported in entacapone-treated healthy volunteers (16, 17). 
However, the physiology of hemodynamic and cardiovascular autonomic responses of 
PD patients may differ from that of healthy volunteers in many respects, perhaps due to 
a high prevalence of autonomic dysfunction (18). In addition, patients are treated with 
L-dopa, a catecholamine pre-cursor, and many also take selegiline, a MAO-B selective 
inhibitor, the concomitant use of which with entacapone may lead to pharmacodynamic 
interactions such as increased dopaminergic adverse effects.
The studies included within this thesis were performed with the aim of further as-
sessing the safety profi le of the peripheral COMT inhibitor entacapone in L-dopa-treated 
patients having mild to moderate PD. The effects of entacapone – both with and with-
out selegiline – on the general tolerability, hemodynamics, cardiac rhythm, and plasma 
catecholamine profi le were investigated. In addition, the effects of peripheral COMT in-
hibition on cardiovascular autonomic function, on cardiorespiratory exercise responses, 
and on plasma catecholamine profi le at rest and during exercise were investigated in PD 
patients receiving selegiline in addition to L-dopa.
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2. REVIEW OF THE LITERATURE
2.1 The essence of Parkinson’s disease (PD)
2.1.1. Epidemiology, neuropathology, and etiology
PD is a chronic degenerative disorder of the nervous system. Reported age-adjusted
incidence and prevalence rates of PD range from 9.7 to 13.8, and from 72 to 259 per 
100 000, respectively, worldwide (19). With an estimated annual incidence rate of 15 and 
prevalence of 166 per 100 000 in Finland (20), it is one of the most common causes of 
neurological disability.
PD is a disorder of late life, and only one-tenth of cases have their onset before the 
age of 50. Thereafter, an age-related steady increase occurs in both the incidence and 
prevalence (21); PD occurs slightly more frequently in men than in women (22).
The neuropathologic hallmarks of PD are neuronal loss and depigmentation, and the 
accumulation of cytoplasmic inclusions called Lewy bodies in SN neurons. Although Lewy 
bodies are essential to the neuropathologic diagnosis (23), their role in the pathogenesis 
of PD is unknown. In the human brain, basal ganglia and their connections form a highly 
complex network of subcortical circuits that play a key role in motor control. The stria-
tum serves as a relay station between cortical motor areas and other parts of the basal 
ganglia. The SN exerts tonic control on the striatum via the dopaminergic nigrostriatal 
tract. Degeneration and the concomitant loss of function of this tract is thought to be the 
main pathophysiologic mechanism leading to the motor manifestations of PD. Although 
PD has been characterized as a “striatal DA defi ciency syndrome,” it is not entirely clear 
whether all of the major symptoms result from a defi ciency of DA alone, or from a defi -
ciency of DA and other neurotransmitters.
In PD, a widespread neuronal degeneration with Lewy bodies also takes place in the 
central and peripheral parts of the autonomic nervous system (24), including the postgan-
glionic sympathetic and intrinsic cardiac neurons (25, 26). Functional imaging studies have 
demonstrated that asymptomatic cardiac sympathetic damage is already present in the 
early stages of the disease (27, 28). The pathophysiology of autonomic dysfunction in PD 
has not been established. The relative roles of sympathetic vs. parasympathetic insuffi cien-
cy are also unclear. According to some authors, parasympathetic dysfunction occurs early 
(29), whereas others suggest a primary involvement of sympathetic autonomics (30).
A diverse array of pathogenetic mechanisms, e.g., defective protein degradation, oxi-
dative cell damage, and failure of mitochondrial complex I, has been suggested to lead 
to nigral cell damage in PD (31). Aberrant protein degradation by the ubiquitin-depend-
ent proteasomal pathway has been implicated, especially in some of inherited forms of 
parkinsonism (32).
The etiology of PD remains elusive. Several putative environmental risk factors, e.g., 
rural living (22), pesticides, and occupational exposure to certain metals (33) have been 
suggested, but none has been established. The discovery that cytotoxin precursor 1-me-
thyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes nigral cell death and severe par-
kinsonism (34) suggests a potential role for environmental toxins in PD. Cigarette smok-
ing is associated with a reduced risk for developing PD (35): A neuroprotective effect of 
some substance(s) in cigarette smoke has been suggested. Caffeine is another substance 
the intake of which is inversely related to risk for developing PD (36).
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Both epidemiological and genealogic data support the contribution of a signifi cant 
genetic component in PD (33, 37). In addition, several forms of familial parkinsonism 
have been recognized in recent years. These are, however, rare, and no specifi c mutations 
linked to these entities have been detected in sporadic PD (38).
2.1.2. Clinical manifestations of PD
Parkinsonism can be defi ned as a clinical syndrome presenting with rest tremor, brady-
kinesia, rigidity, and postural instability. It actually consists of a heterogeneous group of 
disorders, of which idiopathic PD is the most common. Since the initial description of 
symptoms of PD by James Parkinson (39), our view of the clinical characteristics of this 
disease has been signifi cantly revised, and a plethora of non-motor manifestations have 
become widely recognized.
Characteristic symptoms
Bradykinesia (slowness of movement) and akinesia (poverty, absence, or slowed initiation 
of movement) may manifest as diffi culties with manual dexterity, small handwriting, loss 
of facial movements with reduced eye blinking, slow and shuffl ing gait with reduced 
arm-swing, monotonic speech with loss of volume, and dysphagia. The performance of 
sequential and repetitive motor acts is especially affected. Parkinsonian tremor is typically 
a 4–6 Hz resting tremor with an initially asymmetric presentation in either one of the up-
per extremities. Lips, chin, and jaw may be affected as well. Different forms of postural 
or action tremor or both may also be present. Rigidity implies increased resistance to pas-
sive movement throughout the range of motion of a joint. Clinically, it can have different 
qualities, e.g., smooth (“lead pipe”) or rachety (“cogwheel”), and may involve both axial 
and limb muscles. Loss of postural refl exes, stooped posture, rigidity, and bradykinesia/
akinesia may all contribute to postural instability and the associated gait diffi culties which 
are commonly late manifestations of PD (40). Postural instability is typically refractory to 
L-dopa therapy. The pathophysiology of the characteristic motor symptoms of PD is highly 
complex and incompletely understood.
Secondary manifestations
The spectrum of “secondary” (non-motor) manifestations of PD includes dementia, de-
pression, and sleep and autonomic disorders. Most recent data indicate a rather high 
prevalence (up to 40%) for dementia and depression in PD (41). The neurochemical basis 
of these symptoms is likely to be complex and to involve multiple neuronal populations. 
A wide variety of sleep disturbances are also quite frequently encountered (42).
Autonomic manifestations
Autonomic dysfunction in PD has been extensively documented (43, 44). In comparison 
to healthy controls, autonomic involvement in PD patients is much more frequent (45), 
reported to occur in as many as 80 to 100% (46, 47). This section will focus on cardiovas-
cular aspects of parkinsonian autonomic failure.
A high prevalence of cardiovascular autonomic dysfunction has been reported in early 
PD, even in many of the “de novo” (unmedicated) patients (48). Despite some confl icting 
reports (45, 49), most authors have found a positive correlation between cardiovascular 
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autonomic impairment and either the duration or clinical severity of the disease (50–52). 
A progression of sympathetic/parasympathetic cardiovascular dysfunction over a 3-year 
follow-up has also been demonstrated (53).
Dizziness is the most common symptom of autonomic dysfunction in PD (54), found 
to occur in up to 65 to 80% of patients (46). A 20% prevalence for symptomatic orthos-
tatic hypotension in PD has been reported (55). Parkinsonian patients demonstrate lower 
values for mean systolic and diastolic blood pressure (BP) than do healthy controls (56), as 
well as aberrant variation in diurnal hemodynamics (57).
The early reports of autonomic dysfunction in PD based on cardiovascular refl ex test-
ing were controversial (54, 58, 59). Later, most studies in parkinsonian patients have 
shown diminished hemodynamic responses to test stimuli, such as deep breathing, the 
Valsalva maneuver, orthostatic challenge, and isometric work (18, 47, 49, 60, 61), al-
though some have produced mixed results (45, 62). Aberrant cardiac conduction times, 
as well as abnormal diurnal patterns of cardiovascular autonomic control have also been 
demonstrated by use of more sophisticated methods of ambulatory assessment such as 
computerized analysis of Finger Arterial Pressure, and a spectrum of R to R wave (R-R) in-
terval variation (52, 63, 64). Based on results from studies with de novo patients, it seems 
likely that the early stages of PD are not accompanied by clinically signifi cant dysfunction 
of cardiovascular autonomic control (29, 65).
A failure in the rise of plasma NA levels has been demonstrated in PD patients with 
autonomic dysfunction (66). According to some authors, the subgroup of patients with 
orthostatic hypotension show subnormal basal levels of plasma NA as well as diminished 
or absent plasma NA responses to orthostatic challenge (46, 67, 68). Others, however, 
have found no differences in these parameters between PD patients and matched con-
trols (65, 69). Findings on increased hemodynamic sensitivity to exogenous NA in patients 
with orthostatic hypotension, with an up-regulation of peripheral α2-adrenoceptors are 
more consistent (67, 68).
2.1.3. Clinical course
The initial symptoms of PD are presumed to be preceded by a pre-symptomatic period of 
several years. The estimated percentage of nigral cell loss at the onset of clinical signs is 
30 to 50%, with a concurrent 80% reduction in striatal DA (70). Thereafter, a progres-
sive, though highly variable, decline occurs in motor function. A less favorable outcome 
with more rapid functional decline and higher mortality has been suggested for those 
patients presenting with non-tremor manifestations of PD, for instance, gait disturbance, 
postural instability, akinetic-rigid syndrome, and cognitive impairment (71–73).
Before L-dopa, the adjusted mortality rate of PD patients was almost three times that 
of the general population (71). Whether L-dopa has improved life expectancy of parkin-
sonian patients is still a matter of some controversy (74–77).
The fi ve-stage (I–V) Hoehn and Yahr (H&Y) scale is widely used in grading the clinical 
severity of PD (71). In an early series of 204 untreated patients, the median duration of 
disease at stages II through V was 6 to 14 years (71). After introduction of L-dopa therapy, 
however, the median duration of disease at each of these stages was shown to be mark-
edly longer (9 to 18 years) (78). In addition, a much lower percentage of patients on 
L-dopa were either severely disabled or dead after a similar time period, when compared 
to patients without treatment. However, the progressive nature of functional decline in 
PD, measured by means of the total score of the Unifi ed Parkinson’s Disease Rating Scale 
(UPDRS) (79) in both on- and off-states, remains unaffected by treatment (73).
16
2.1.4. On the diagnostics of PD
Several clinical features are considered to support the diagnosis of PD (Table 1). However, 
an early diagnosis is sometimes challenging due to the broad phenotypic variability of PD, 
the lack of a disease-specifi c biologic marker, and the overlap of clinical features between 
different parkinsonian syndromes. No single feature is suffi cient in distinguishing PD from 
other forms of parkinsonism (80). The evidence from post-mortem studies has shown 
that many clinically diagnosed cases do not conform to the neuropathologic criteria for 
the disease and vice-versa (81–83).
Several sets of clinical criteria for diagnosing PD have been proposed, although most 
have not been evaluated for their validity and reliability. Some authors have suggested 
that the diagnostics should rely mainly on excluding patients with atypical features or 
poor response to L-dopa (84, 85). Regardless of the set of criteria used, a trade-off al-
ways exists between sensitivity and specifi city (80, 83). The United Kingdom Parkinson’s 
Disease Society Brain Bank clinical diagnostic criteria for PD have been the most widely 
adopted (81) (Table 1).
Table 1. The United Kingdom Parkinson’s disease Society Brain Bank clinical
Diagnostic criteria, modifi ed from (81).
Inclusion criteria Exclusion criteria Supportive criteria
Bradykinesia History of (≥ 3 for defi nite diagnosis)
   and (one or more)    Repeated strokes Unilateral onset
Rigidity    Repeated head injury Rest tremor
Rest tremor (4–6 Hz)    Encephalitis Progressive course
Postural instability Oculogyric crises Persistent asymmetry
Neuroleptic Rx at onset Excellent response to L-dopa
More than one relative with PD Long-lasting response
(≥ 5 years) to L-dopa
Sustained remission L-dopa-induced chorea
Strictly unilateral features after
3 years
Long clinical course (≥10 years)
Supranuclear gaze palsy
Cerebellar signs
Early severe autonomic
involvement
Early severe dementia
Babinski sign
CT: cerebral tumor or
hydrocephalus
No L-dopa response
(large doses)
MPTP exposure
PD, Parkinson’s disease; CT, computerized tomography; MPTP, 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine
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The differential diagnostics constitutes the exclusion of other causes for parkinsonism 
using medical history, clinical examination, assessment of response to drug therapy, and 
long-term follow-up (Table 1). After 5 years from the onset of symptoms, the clinical di-
agnosis is possible in most cases (86). The use of radio- and functional imaging methods, 
biochemistry, clinical physiology, and neurophysiology may be considered in a selective 
group of cases, although these are generally unnecessary. [18F]6-fl uoro-L-dopa imaging 
with positron emission tomography directly measures DA terminal integrity in the stria-
tum, but it is seldom used in clinical practice due to its relatively high cost and limited 
availability. Single photon emission computerized tomography with, for instance, a [123I]β-
CIT (2β-carboxymethoxy-3β(4-iodophenyl)tropane) tracer is clinically more feasible, and 
shows adequate sensitivity in discriminating PD from other causes of parkinsonism (87). 
Thus far, genetic testing for specifi c mutations known to cause familial parkinsonism is 
not routinely warranted in sporadic disease.
Major clinical entities that should be differentiated from PD include essential trem-
or, vascular & drug-induced parkinsonism, Alzheimer’s disease, and Parkinson-plus syn-
dromes, which include multiple system atrophy (MSA), progressive supranuclear gaze 
palsy, diffuse Lewy body dementia, and corticobasal ganglionic degeneration. In contrast 
to PD, Parkinson-plus syndromes demonstrate a more widespread neuropathologic in-
volvement and “atypical” clinical features, e.g., early dementia, other cortical signs, se-
vere autonomic failure, marked postural instability, and poor response to L-dopa.
2.2. Treatment of PD
The modern treatment of PD is mainly targeted at enhancing striatal dopaminergic activ-
ity. Replacement of striatal DA with L-dopa is the principal type of dopaminergic therapy, 
whereas the DA receptor agonists are able to “mimic” the actions of DA in the striatum. 
MAO-B inhibitors reduce the degradation of striatal DA, thereby enhancing its actions. 
COMT inhibitors improve L-dopa entry into the brain by inhibiting its peripheral catab-
olism. Some novel experimental drugs have non-dopaminergic modes of action, e.g., 
the antagonists of N-methyl-D-aspartate (NMDA) or adenosine A2A receptors. A concise 
review is available of the pharmacological properties of current antiparkinsonian drugs 
(88).
Functional stereotactic (deep brain) surgery for PD is targeted at specifi c sites in the 
basal ganglia or thalami. A modern approach is to insert a deep brain-stimulating device 
into the target site by a stereotactic method. Surgical treatment has been recognized as 
having benefi cial effects in the symptomatic control of advanced PD (89), but it is gener-
ally reserved for cases with disease refractory to drug therapy or for those with function-
ally disabling motor complications.
2.2.1. L-dopa
The emergence and principles of therapy
In the early 1960s appeared the fi rst report on the anti-akinetic effect of intravenous L-
dopa in PD patients (1). It was not until the fi ndings by Cotzias et al., demonstrating the 
clinical effi cacy of high oral doses of both racemic dopa and L-dopa (90, 91), that L-dopa 
established its position as a major drug in the management of PD.
Concise reviews are available on the pharmacokinetics of L-dopa (92, 93). Orally ad-
ministered L-dopa is predominantly absorbed from the proximal small intestine by an ac-
tive, saturable carrier system of large neutral amino acids (LNAAs) (94). It then undergoes 
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extensive metabolism (92): At least 80% of the dose enters the catecholamine degrada-
tion pathways (95). The gut wall is the fi rst barrier, at which the majority of the drug is 
rapidly metabolized to DA by DDC (96). The oral bioavailability of L-dopa is therefore low 
(97). After absorption, plasma L-dopa is rapidly catabolized (mostly to DA) with an elimi-
nation half-life (t1/2) of 0.8 to 1.7 hours (98, 99). In analogy with the gut wall, circulating 
L-dopa is taken up and transported through the BBB by the LNAA carrier system (100). At 
both these sites, other LNAAs can competitively inhibit the transport of L-dopa.
In 1967, inhibitors of extracerebral DDC with poor penetration through the BBB were 
demonstrated to enhance the L-dopa-induced increase in brain DA levels (101). Two ef-
fective inhibitors of peripheral DDC became clinically available, namely benserazide [(±)-
D,L-seryl-(2,3,4-trihydroxybenzyl)hydrazine] and carbidopa (1-α-methyldopa-hydrazine) 
(91, 102, 103); their pharmacological and clinical effects are nearly identical (104). The 
main site of action of DDC inhibitors seems to be the intestinal wall (105). Use of a DDC 
inhibitor as an adjunct to L-dopa results in reduced formation of peripheral DA with less 
DA-related peripheral adverse effects, e.g., nausea and vomiting (106). More L-dopa thus 
becomes available for transport through the BBB into the brain, where decarboxylation to 
DA can freely occur (93). The bioavailability of L-dopa is much improved, and the clinical 
benefi t is achieved despite drastic reductions in total daily dosage (107).
In the brain, DDC rapidly decarboxylates L-dopa to DA. According to the DA storage 
hypothesis, this neurotransmitter is then stored presynaptically until its fi ring-coupled 
vesicular release into the synaptic cleft (108). Evidence is unequivocal that in the par-
kinsonian brain exogenous L-dopa does increase the concentration of striatal DA (109). 
However, several key issues related to the mechanisms of action of L-dopa, such as de-
carboxylation sites, the roles of the vesicular vs. extravesicular DA pool, phasic vs. tonic 
DA-mediated responses, and the contribution of different DA receptor subtypes to the 
therapeutic effect remain incompletely understood.
Clinical effi cacy and shortcomings of long-term treatment
L-dopa is at present the most effective drug in the treatment of motor symptoms of PD 
(110, 111). Patients usually demonstrate a consistent clinical response to the drug. In 
general, bradykinesia/akinesia, rigidity, and tremor all respond to L-dopa therapy, where-
as postural instability is usually unresponsive. L-dopa therapy has been associated with 
reduced progression of disability, morbidity, and mortality (75, 76).
In early PD, a smooth, long-duration response to L-dopa occurs, presumably due to 
presynaptic storage and tonic release of DA from the unaffected axons (92). In the long 
term, motor response oscillations and abnormal involuntary movements emerge in a sig-
nifi cant number of patients (2). It is thought that after 5 years of L-dopa as many as 
50% or more develop motor response complications (112, 113). These constitute a major 
therapeutic challenge.
The most common type of motor complication is the “wearing-off” or “end-of-dose” 
phenomenon, in which the initially stable diurnal motor state during intermittent L-dopa 
dosing is replaced by a progressive shortening of response to each dose. In late-stage dis-
ease, the motor response to the drug may closely correlate with its plasma levels (114).
Involuntary movements such as dyskinesia and dystonia may also emerge. One large 
prospective trial observed dyskinesias in one-third of the patients after approximately 1.5 
years of L-dopa therapy (115). The most common form is the peak-dose dyskinesia (116), 
in which the peaks for plasma L-dopa and clinical effect coincide with typically chorei-
form movements. Dystonia presents as sustained muscle contraction leading to abnormal 
twisting or posturing of a body part.
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The exact pathophysiology of motor fl uctuations in PD is unknown. It has been sug-
gested that the combined effects of the neurodegenerative process and long-term expo-
sure to pulsatile plasma levels caused by intermittent L-dopa administration precipitate 
the emergence of motor fl uctuations and dyskinesia (114, 117). Progressive loss of pr-
esynaptic dopaminergic terminals and their reduced capacity to buffer changes in L-dopa 
levels both in the plasma and in the brain are thought to lead to end-of-dose type fl uctua-
tions, in which tonic DA receptor stimulation is replaced by a phasic one (118, 119). Phar-
macokinetic mechanisms have also been implicated (120). Involvement of other complex 
mechanisms (changes in postsynaptic gene expression, changes in number and sensitivity 
of dopaminergic/non-dopaminergic receptors) in the genesis of motor complications and 
dyskinesia is also under speculation.
Several attempts have been made to improve the pharmacokinetic profi le of L-dopa. 
CR preparations (Sinemet CR, Madopar HBS) are meant to provide a more constant eleva-
tion of L-dopa plasma levels, but the bioavailability of L-dopa is reduced, and its absorp-
tion becomes even more erratic than with standard preparations (121). In theory, use of 
CR L-dopa might be less likely to result in development of motor complications, though 
no such benefi t has been observable in long-term studies (122). To improve the erratic 
absorption of the drug, continuous duodenal infusion of L-dopa (Duodopa®) is under 
investigation; results have been encouraging (123).
The putative disease-modifying effect of L-dopa remains an area of controversy (114, 
124). A theoretical concern is that L-dopa may promote neuronal degeneration in PD 
through several mechanisms (125, 126). At present, however, no conclusive evidence 
exists that long-term L-dopa therapy is either toxic to nigral neurons or contributory to 
motor complications in PD (114, 124, 127).
2.2.2. Other drugs for PD
Compounds with anticholinergic properties were the fi rst drugs with therapeutic effi cacy. 
Although their precise mechanisms of action are unknown (110), anticholinergics are 
thought to block central muscarinic receptors and thereby reduce striatal cholinergic pre-
ponderance. In comparison to L-dopa, the clinical effi cacy of anticholinergics is modest. 
They appear most to benefi t dystonia, rigidity, and tremor (128). Anticholinergics have 
undesirable adverse cognitive effects (129), thus limiting their therapeutic potential.
Schwab and co-workers were the fi rst to report the antiparkinsonian effects of aman-
tadine hydrochloride (130). Its mechanism of action in PD is likely to be complex (88, 
128). Amantadine has effi cacy both as monotherapy and as an adjunct to L-dopa (131). 
It has also been reported to reduce L-dopa-induced dyskinesia in advanced PD, possibly 
through its NMDA-receptor-blocking properties (132).
The central effects of DA are mediated through DA receptors, of which there are at 
least fi ve types: D1- (D1, D5) and D2-like (D2, D3, D4) (88, 133). DA agonists “mimic” the 
action of DA by exerting direct effects on these receptors, each having a unique affi nity 
profi le (88). The antiparkinsonian effi cacy of DA agonists seems to derive mainly from 
stimulation of the D2-receptor subtype, whereas D1 stimulation has been linked to the 
induction of dyskinesia (134). The exact roles for D3, D4, and D5 remain unknown (135).
DA agonists (bromocriptine, pergolide, gabergoline, pramipexole, ropinirole) are clini-
cally effective both as monotherapy in early PD and as an add-on therapy to L-dopa in 
more advanced disease (110, 111). Their early introduction as a sole agent or as an L-
dopa add-on has also been shown to delay the occurrence of motor complications, for 
instance, dyskinesia, in comparison to monotherapy with L-dopa (110, 112, 136, 137). 
DA agonists are, however, less effi cacious than L-dopa and lack its clinical potency in late-
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stage PD (112, 117). Therefore, L-dopa supplementation is eventually required in most 
patients, and only some 20% are able to remain on agonist monotherapy for 5 years 
(111, 112, 128).
DA agonists have been proposed to have several neuroprotective effects (117), but 
none have been established in clinical use.
Apomorphine is yet another DA agonist. Although not orally effective, it can be ad-
ministered subcutaneously, and as such has shown effi cacy in treating motor complica-
tions of long-standing PD (138).
Monoamine oxidase (MAO) catalyzes the oxidative deamination of primary amines, 
such as endogenous amine neurotransmitters (NA, DA), hormones (adrenaline), and ex-
ogenous dietary amines (tyramine, tryptamine). Two distinct subtypes of the enzyme exist 
(139). MAO-B is the subtype that predominates in the human brain and platelets (140, 
141).
At daily doses of 5 to 10 mg, selegiline (N-propynyl-metamphetamine), a relatively 
selective inhibitor of MAO-B devoid of any tyramine-potentiating effect (142), has symp-
tomatic effi cacy in PD. Selegiline is able to inhibit the metabolism of DA in the brain, 
thereby increasing its levels both in the SN and basal ganglia (143). Other mechanisms 
of action such as inhibition of neuronal re-uptake of DA have also been suggested (144). 
Because selegiline acts irreversibly on MAO-B, the rate of recovery of enzymatic activity 
is slow (145).
Selegiline can extend the symptomatic effects of L-dopa and improve clinical disability 
in L-dopa-treated parkinsonian patients who show “wearing-off” fl uctuations (146). The 
daily dosage of L-dopa can usually be reduced by 10 to 30%. The magnitude of improve-
ment with selegiline is, however, modest to moderate at best, and according to some 
authors, its clinical benefi ts as add-on therapy are eventually lost (147). Selegiline has 
antiparkinsonian effi cacy also as monotherapy (111, 148), and delays the need to initiate 
L-dopa (74, 148, 149).
Several neuroprotective properties for selegiline have been suggested (150, 151), but 
none has been proven.
As add-on therapy to L-dopa, selegiline may aggravate or induce dopaminergic ad-
verse events (AEs): nausea, orthostatic hypotension, dyskinesia, hallucinations, confusion 
(146, 152). These usually respond favorably to reductions in L-dopa dosage. Selegiline 
monotherapy is better tolerated, but may cause dizziness, dry mouth, or insomnia. An-
ecdotal reports exist on the occurrence of a serotonin- or phaeochromocytoma-like syn-
drome in patients treated with selegiline plus either a 5-hydroxytryptamine (serotonin) 
uptake inhibitor or the combination of a sympathomimetic and a tricyclic antidepressant 
(153, 154).
Rasagiline, another irreversibly acting MAO-B inhibitor, has recently become clinically 
available. Like selegiline, it has shown effi cacy as an L-dopa adjunct in PD patients with 
motor fl uctuations (155).
One of the most recent additions to the pharmaceutical arsenal of PD are the inhibi-
tors of the COMT enzyme (14, 156–158). COMT inhibitors improve L-dopa bioavailability 
(area under the plasma concentration time curve = AUC) by reducing its COMT-depend-
ent metabolic loss. Entacapone is an inhibitor of extracerebral COMT, while tolcapone is 
able – at least to some extent – to penetrate the BBB and act also in the central nervous 
system. Both drugs signifi cantly improve the clinical effi cacy of L-dopa in patients with 
end-of-dose type motor fl uctuations. COMT inhibitors, entacapone in particular, are re-
viewed in Section 2.3.
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2.2.3. Antiparkinsonian drugs: effects on cardiovascular autonomics
Numerous reports exist on the effects of antiparkinsonian drugs on cardiovascular auto-
nomic function in PD. The effects of L-dopa are controversial. According to many reports, 
acute or chronic administration of L-dopa has no discernible effect on baroreceptor refl ex 
function (59), cardiovascular autonomic parameters (18, 30, 49, 58), hemodynamic ad-
aptation or serum NA response to orthostatic challenge (46, 159). Signifi cant effects have 
also been reported. Long-term L-dopa therapy has been shown to reduce BP in PD (160), 
possibly through centrally mediated mechanisms (161). Blunting of plasma NA response 
by dopaminergic drugs (including L-dopa) has also been suggested (69). Benefi cial effects 
of chronic L-dopa administration on cardiovascular autonomic function, such as amelio-
ration of heart rate (HR) response to deep breathing (162) and diminution of previously 
abnormal orthostatic BP fall (61), have also been reported.
Orthostatic hypotension is a widely recognized side-effect of DA agonists. It has oc-
curred in one-third of the patients at the start of therapy, although only approximately 
one-third of these were symptomatic (163). Lisuride has reduced plasma NA levels, as 
well as blunted plasma NA and cardiovascular responses to standing up in de novo PD 
patients (164). Bromocriptine, the effects of which are probably the most extensively 
studied, has reduced both supine and standing systolic BP in PD, possibly through central 
dopaminergic or α-adrenolytic mechanisms (165). Bromocriptine has also augmented the 
abnormal BP fall during an orthostatic test in previously untreated patients (61).
Chronic administration of selegiline has diminished cardiovascular autonomic (espe-
cially sympathetic) responses (166) and is associated with severe orthostatic hypotension 
in the majority of patients, with an abolition of this effect after withdrawal of the drug 
(167). In untreated PD patients, an augmentation of systolic BP fall after tilting, and 
a blunting of systolic BP response to isometric work have occurred after 6 months on 
selegiline. Changes in these responses reversed to baseline after discontinuation of the 
drug (61).
2.3. Catechol-O-methyltransferase (COMT) inhibitors
in treatment of PD
Inhibition of the COMT enzyme is a novel approach in the symptomatic treatment of PD. 
Concise reviews on the pharmacology of this enzyme and its inhibitors (7, 14, 168), and 
on the role of these drugs in the therapy of PD are available (157, 158, 169, 170).
2.3.1. COMT enzyme: localization and molecular structure
COMT, which catalyzes the conversion of catecholamines (adrenaline, NA, DA) to their 
corresponding O-methylated amines (4–6), is an intracellular enzyme mostly present in a 
soluble (S-COMT), but also in a membrane-bound (MB-COMT) form (6, 7, 14, 171).
COMT is widely distributed in mammalian tissues (14, 15): The highest COMT activ-
ity is in the liver, followed by the kidneys and the gastrointestinal tract (168, 172, 173). 
It is abundantly present also in the mammalian brain. In the striatum, S-COMT activity 
predominates in the glial cells, whereas neuronal activity mainly derives from MB-COMT 
(174, 175).
Mammals have a single COMT gene localized to the long arm of chromosome 22 
(176, 177). This gene codes for both S- and MB-COMT, and is expressed in two transcripts 
of different lengths (178). Some of the extra amino acid residues present in MB-COMT 
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may be responsible for anchoring the enzyme into cellular membranes (179). COMT is 
a single-domain protein, and its active site – formed by a catalytic site of a few amino 
acids and the binding domain for the coenzyme S-adenosyl-L-methionine – is located in 
a groove on the enzyme surface (14, 180).
COMT catalyzes the transfer of the methyl group from S-adenosyl-L-methionine to 
one of the hydroxyl groups of the catechol substrate in the presence of Mg2+ (7). The two 
COMT isoforms differ in their substrate selectivity and enzymatic capacity: MB-COMT ex-
hibits a markedly higher affi nity for catechols than does its soluble counterpart (181) and 
may therefore be more important in the metabolism of catecholamines (171).
Human beings have two COMT alleles (low activity = COMTL; high activity = COMTH) 
that demonstrate autosomal co-dominant inheritance (14, 182). COMTL associates with 
thermolability of the enzyme (182). A single codon polymorphism in the COMT gene has 
been identifi ed (183); COMT polymorphism and enzymatic activity vary between races 
and ethnic groups (184). Controversy has arisen over an association between COMTL 
homozygosity and increased susceptibility to PD (185, 186).
2.3.2. COMT enzyme: biological function
COMT and MAO are particularly important in the metabolic transformation of catecho-
lamines (187, 188). The general role of COMT is the elimination of biologically active or 
toxic catecholamines and some of their hydroxylated metabolites; in various tissues, it 
serves as a modulator of catecholaminergic activity. MB-COMT is partially responsible 
for the termination of dopaminergic and noradrenergic neurotransmission, whereas the 
high-capacity S-COMT is mainly responsible for the elimination of biologically active or 
toxic (particularly exogenous) catechols and metabolites (156). In the brain, COMT may 
regulate the levels of DA and NA and therefore play a role in mood, behavior, and other 
mental processes (14, 189). In the kidneys, COMT seems to be important in the DA-medi-
ated regulation of renal sodium excretion (190).
Metabolism of endogenous catecholamines and other substrates 
Many endogenous compounds are substrates for COMT. These include amino acids with 
a catechol moiety (levodopa), naturally occurring catecholamines (DA, NA, adrenaline) 
(6), their hydroxylated metabolites, and catecholestrogens (191). However, in physiologi-
cal situations, the neuronal reuptake (uptake1) of DA and other catechols dominates 
among metabolic inactivation pathways (COMT and MAO in particular) as the most ef-
fi cient clearance system for locally released catecholamines (168, 188, 192). Uptake1 is 
also essential for the proper function of MAO in providing substrates for intraneuronal 
oxidative metabolism (168). In vivo studies with experimental animals have shown that 
COMT inhibition has no discernible effect on clearance of NA, adrenaline, or DA, and also 
that the contribution by uptake1 to removal of circulating catecholamines depends on 
whether the systemic or pulmonary circulation is considered (193). Accordingly, inhibition 
of either MAO or COMT alone has little if any effect on the removal of these catecho-
lamines on their passage through the systemic and pulmonary circulation. Although the 
combined inhibition of both of these enzymes has been highly effective in reducing the 
pulmonary clearance of NA and DA, only minor decreases have occurred in the total-body 
clearance of all three catecholamines (194). The metabolic disposition of catecholamines 
is illustrated in Fig. 1.
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Fig. 1. Synthesis and metabolic disposition of catecholamines. Enzymes: AAAD/DDC, aro-
matic L-amino acid decarboxylase = dopa decarboxylase; DBH, dopamine β-hydroxylase; 
PNMT, phenylethanolamine-N-methyltransferase; COMT, catechol-O-methyltransferase; 
MAO, monoamine oxidase; AD, aldehyde dehydrogenase; AR, aldehyde reductase. Com-
pounds: 3-OMD, 3-O-methyldopa; DOPAC, 3,4-dihydroxyphenylacetic acid; 3-MT, 3-meth-
oxytyramine; HVA, 3-methoxy-4-hydroxyphenylacetic acid; DOMA, 3,4-dihydroxymandelic 
acid; VMA, 3-methoxy-4-hydroxymandelic acid; DHPG, 3,4-dihydroxyphenylethylene glycol; 
MHPG, 3-methoxy-4-hydroxyphenylethylene glycol. Metabolic intermediates []: DOPGAL, 3,4-
dihydroxyphenylglycoaldehyde; MOPGAL, 3-methoxy-4-hydroxyphenylglycoaldehyde. Most
catecholamines and their metabolites may also be conjugated to either sulfates or glucuro-
nides.
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Effects on L-dopa and other exogenous substrates
COMT serves as a protective barrier against detrimental effects of xenobiotics (14). Its 
exogenous substrates include dietary and medicinal compounds, for instance, ascorbic 
acid, fl avonoids, and several catechol-structured drugs such as L-dopa, dobutamine, iso-
prenaline, benserazide, carbidopa, apomorphine, and L-threo-DOPS.
Although in physiological circumstances COMT apparently does not contribute great-
ly to the clearance of endogenous catecholamines, it does play a defi nite role in the 
removal of some exogenous catechol-structured drugs like isoprenaline (193). Likewise, 
COMT plays a major role in the metabolism and fate of exogenously administered L-dopa. 
In the periphery, L-dopa is metabolized mainly by two enzymatic pathways working in 
parallel: DDC-catalyzed decarboxylation to DA, and COMT-mediated O-methylation to 
3-O-methyldopa (3-OMD). During L-dopa therapy, the pharmacokinetic advantages of 
concomitant peripheral DDC inhibition are therefore partially offset by a shift in a major 
portion of L-dopa metabolism towards the COMT pathway (168, 195, 196). The major 
metabolite 3-OMD (196, 197) is formed in proportion to the administered dose of L-dopa 
(198). 3-OMD has a long half-life of approximately 15 hours (199), but no intrinsic an-
tiparkinsonian activity (200). It has also been established that exogenous 3-OMD reduces 
the effi cacy of L-dopa therapy in PD (201). The mechanism of this antagonism may be 
that, being an LNAA, 3-OMD can competitively inhibit the transport of L-dopa across the 
intestinal mucosa and through the BBB (202). However, 3-OMD constitutes only a minor 
portion (about 10%) of the total LNAAs and probably has a negligible effect on the trans-
port/uptake of L-dopa (9, 201, 203, 204).
2.3.3. COMT inhibition: a means to modify L-dopa clearance
Therapeutic principles
The rationale of selective COMT inhibition as an adjunct therapy to L-dopa in PD, and 
the benefi cial effects of COMT inhibitors on the pharmacokinetics of L-dopa have been 
extensively reviewed (9, 14, 157, 205, 206). The acknowledgment of several problems 
associated with L-dopa treatment has led to formulation of the following therapeutic ra-
tionale: 1) As a catechol, L-dopa is subjected to extensive degradation by DDC and COMT 
(Fig. 2a); its pharmacokinetic properties: extensive peripheral metabolism, short t1/2, poor 
bioavailability (92), are therefore therapeutically unfavorable for providing a sustained 
clinical response. 2) L-dopa dose-related (“end-of-dose”) motor complications emerge in 
many patients during chronic administration of the drug (114). 3) Although COMT activ-
ity is much lower than that of DDC, it has been supposed that competition over the sub-
strate L-dopa may take place in the gut wall (207). When peripheral decarboxylation of L-
dopa is inhibited by benserazide or carbidopa, L-dopa is predominantly O-methylated to 
3-OMD (92) (Fig. 2b). The COMT-catalyzed pathway therefore contributes signifi cantly to 
the metabolic loss of peripheral L-dopa (158, 208) (Section 2.3.2.). Combining a COMT 
inhibitor with L-dopa and a DDC inhibitor causes the loss of L-dopa through 3-O-meth-
ylation to decrease and the bioavailability of L-dopa to improve (209) (Fig. 2c). Improved 
bioavailability leads to improved brain entry of L-dopa and allows a decrease in the dose 
of L-dopa without loss in its clinical effi cacy (L-dopa “sparing” effect). Furthermore, the 
dose interval of L-dopa can be prolonged (156).
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In the treatment of “end-of-dose” motor fl uctuations, COMT inhibition has been an 
effective approach in providing a more prolonged maintenance of L-dopa plasma levels, 
more continuous dopaminergic input into the striatum, and fi nally a longer clinical re-
sponse to the drug (169, 170).
COMT inhibitors
The fi rst compounds found to show COMT inhibitory properties include pyrogallol and its 
derivatives (gallic acid, N-butyl-gallate), catechol derivatives, and tropolones (7). Some of 
these, such as N-butyl-gallate, demonstrate clinical effi cacy in PD (210). These early com-
pounds had qualities, however, that made them inappropriate for human use, namely 
lack of selectivity, low potency, and short duration of action in vivo (7, 14). Many of them 
were also rather toxic.
It has been demonstrated that catechols containing electronegative substituents such 
as NO2 are potent inhibitors but poor substrates of COMT (209, 211). In the late 1980s, 
a class of highly potent and selective COMT inhibitors was developed. These compounds 
were bisubstituted catechols incorporating a nitrocatechol moiety (NO2 in the 5’-posi-
tion) as a key molecular structure (Fig. 3) (209, 212). The nitrocatechol derivatives enta-
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Fig. 3. Chemical structure of L-dopa, peripheral dopa decarboxylase (DDC) inhibitors carbidopa 
and benserazide, and some nitrocatechol-structured catechol-O-methyltransferase (COMT) 
inhibitors, with the 5’-nitrocatechol moiety, essential for highly selective COMT inhibition, 
shown. -R, side-chain. The aromatic side-chain of tolcapone renders it more hydrophobic than 
are the other two nitrocatechol compounds.
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capone [OR-611; (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrocinnamamide], niteca-
pone [OR-462; 3-(3,4-dihydroxy-5-nitro-benzylidene)-2,4-pentanedione], and tolcapone 
(Ro 40-7592; 4’-methyl-3,4-dihydroxy-5-nitro-benzophenone) are orally active, selective, 
highly potent, and reversibly acting inhibitors (156, 173, 181, 213–216). Their selectivity 
for COMT is much higher (by several magnitudes) than that of other catecholamine-me-
tabolizing enzymes (212, 214-217). All of these compounds demonstrate a dose-depend-
ent inhibitory action on the enzyme (156, 212, 215, 217). Tolcapone has more potency 
and a longer duration of action than do the other two drugs (14, 218, 219).
Ample data from experimental animals indicate poor BBB penetration – and therefore 
a principally extracerebral mode of action – for entacapone (8, 216, 218). Nitecapone 
demonstrates similar properties (173, 212, 217, 220). Tolcapone is able (at least to some 
extent) to penetrate the BBB and inhibit COMT also in the brain (8, 214, 218, 219); this 
has been demonstrated in humans (221). Central COMT inhibition seems, however, to 
be of minor signifi cance, and the therapeutic effi cacy of COMT inhibitors most probably 
derives from their peripheral actions only (158, 206).
Animal data are consistent with the effective COMT inhibition of each of these com-
pounds. Markedly reduced formation of 3-OMD, dose-dependent prolongation of the t1/2 
of L-dopa, signifi cantly improved L-dopa bioavailability, and increased levels of striatal DA 
have all been observed (212, 220, 222, 223). Accordingly, pre-treatment with either en-
tacapone or tolcapone results in a substantially increased striatal uptake of [18F]6-fl uoro-
L-dopa (an analogue of L-dopa) (224, 225).
Unilateral 6-hydroxydopamine (6-OHDA)-induced lesion of the nigrostriatal pathway 
is a widely used rodent model of PD (226). Dopaminergic agents such as L-dopa can 
induce contralateral circling behavior in 6-OHDA-lesioned rats. The COMT inhibitors en-
tacapone, tolcapone, and nitecapone markedly potentiate this L-dopa-induced rotational 
behavior (220, 227), consistent with their effects on striatal DA levels.
2.3.4. COMT inhibitors: pharmacodynamic effects in humans
COMT activity
In healthy humans and patients with PD, modern COMT inhibitors show a rapid, con-
sistent, dose-dependent, and fully reversible inhibition of erythrocyte COMT, both after 
single and after repeated dosing with these drugs (228–232). A 200-mg dose level of 
entacapone has been reported to lead to an inhibition of erythrocyte COMT activity of 
approximately 40% (232, 233).
L-dopa pharmacokinetics
The effects of entacapone on L-dopa pharmacokinetics and DA metabolism are
summarized in Table 2. In PD patients, the t1/2 of L-dopa is prolonged by 25 to 75%,
and its AUC (bioavailability) is increased accordingly (204, 232–235). The absorption ki-
netics, i.e., peak plasma concentration (Cmax) or the time to peak plasma concentration 
(Tmax), of L-dopa generally remain unchanged by entacapone (Table 2) (157, 204, 232, 
236, 237).
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The changes in L-dopa pharmacokinetics after a single dose of entacapone remain practi-
cally unaltered when entacapone is administered repeatedly with L-dopa (204, 234, 239). 
During repeated, simultaneous dosing of the two drugs at 2- to 4-hour intervals, the 
mean daily concentration of L-dopa rose, with a 30 to 50% decrease in the peak-trough 
variation in its plasma levels observable (158, 204, 206). No accumulation of L-dopa 
plasma levels occurs, however, from one day to the next (204, 241).
In general, entacapone has similar effects on the pharmacokinetics of both CR and 
standard L-dopa formulations (242, 243). Unlike the case with standard L-dopa, however, 
entacapone seems to raise the Cmax of CR L-dopa (243, 244).
During long-term administration of entacapone 200 mg with each dose of L-dopa, 
plasma levels of 3-OMD are reduced, dose-dependently (236), by some 50% (Table 2) 
(11, 204, 234, 239, 240).
Entacapone alters the metabolic profi le of peripheral DA. Plasma levels of dihydroxy-
phenylacetic acid (DOPAC) become markedly increased (Table 2), indicating a shift in DA 
metabolism towards MAO-catalyzed degradation (Fig. 1). A moderate decrease in the 
AUC of homovanillic acid (HVA, the fi nal product of DA metabolism) occurs after addition 
of entacapone to L-dopa therapy.
Table 2. Effects of entacapone 200 mg on the pharmacokinetics of L-dopa and dopamine 
metabolism in humans.
Dosing scheme, dose range L-dopa AUC of Reference
(Duration of treatment) AUC t1/2 Tmax Cmax 3-OMD DOPAC HVA
Healthy subjects
   Single, E 50-400 mg +42% NC NC NC -46% +214% NC 236
   Single, LD 50-250 mg +30 -
+40%
NC -
+125%
-28% -
NC
-55% -
-60%
+200% -
+260%
-75% -
NC
238
PD patients
   Single +46% +32% +181% -33% 235
   Single
   Repeated (8 weeks)
+48%
+43%
+75%
+59%
NC
-33%
NC
-59%
204
   Single
   Repeated (1 week)
+38%
+40%
NC NC
NC
-44%
-24%
-28%
234
   Single, E 50-400 mg +23% +39% NC NC -13% +77% -32% 232
   Single
   Repeated (4 weeks)
+29%
+21%
NC NC NC
NC
-45%
-21% 239
   Repeated (4 weeks) +35% +32% NC NC -63% +201% -17% 240
   Repeated, E 100-400 mg
   (2 weeks)
+27% +26% -54%
233
AUC, area under the concentration time curve; t1/2, elimination half-life; Tmax, time to peak 
plasma concentration; Cmax, peak plasma concentration; 3-OMD, 3-O-methyldopa, DOPAC, 
dihydroxyphenylacetic acid; HVA, homovanillic acid; E, entacapone; LD, L-dopa; NC, not (sig-
nifi cantly) changed
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2.3.5. The role of the COMT inhibitor entacapone in treatment of PD:
clinical evidence
Effi cacy
Both entacapone and tolcapone are effi cacious in parkinsonian patients with end-of-dose 
motor fl uctuations (158, 169, 245).
Several factors favor the simultaneous administration of entacapone with each dose 
of L-dopa: First, these two drugs have pharmacokinetic similarities such as a t1/2 of about 
one hour; second, the COMT inhibition by entacapone is rapidly reversible; third, a close 
correlation exists between plasma entacapone level and level of COMT inhibition (92, 
158, 235, 236, 246). In comparison to entacapone’s, both the t1/2 and the COMT inhibi-
tory effect of tolcapone are longer. The drug is therefore always administered in three 
daily doses, irrespective of L-dopa dosing frequency (157, 158, 211).
Entacapone 200 mg has been shown to be the most effective dose, both pharma-
cokinetically and clinically (232, 246). No further clinical benefi t results from higher doses 
(170, 232, 247).
In early clinical studies of fl uctuating PD patients, both single and repeated dosing 
of entacapone signifi cantly reduced the motor disability by prolonging the duration of 
motor response to each dose of L-dopa (the ON-time), as measured by the UPDRS part III 
and other tests of motor function such as tapping and walking (204, 234, 239, 240, 247). 
Entacapone has lengthened the ON-time of each dose of L-dopa by 30 to 40 minutes 
(170), without affecting the magnitude of motor response (232, 239).
Table 3. Effi cacy of entacapone in randomized, double-blind, placebo-controlled studies.
Design &
Duration
Arm Patients (n) ON-timea
increase (h)
OFF-timeb
decrease (h)
Motor UPDRS
changec
ADL
changec
Reference
∆ ∆ ∆ ∆
Cross-over
4 weeks
E
P 23
2.5
0.4 2.1
** NA NA NA
240
Parallel-group
6 months
E
P
103
102 ~1
** ~1 -2.4* -1.1*
10
Parallel-group
6 months
E
P
85
86
1.4
0.2 1.2
***
1.3
0.1 1.3
***
-3.0
+4.2 *
-1.7
-0.4 **
11
Parallel-groupd,
6 months
E
P
129
74
1.7
0.9 ~1
*
1.6
0.9 ~1
*
-3.3
-0.1 **
-1.1
-0.2 *
248
Parallel-groupd
6 months
E
P
115
57
1.3
0.1
1.2**
1.1
0.3
*
-4.5
-4.3
NS
-0.5
-1.1
NS
249
a period when mobile or capable of moving with relative ease; b period when immobile or 
incapable of moving with relative ease. c reduction means improvement, increase indicates 
worsening; d patients with motor fl uctuations shown.
∆, overall treatment effect (entacapone vs. placebo) ; UPDRS, Unifi ed Parkinson’s disease Rat-
ing Scale; ADL, Activities of Daily Living; E, entacapone; P, placebo. Signifi cance levels of the 
treatment effect shown: *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, not signifi cant.
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The relevant effi cacy data from fi ve double-blind, randomized, placebo-controlled 
studies (10, 11, 240, 248, 249) are summarized in Table 3. These studies corroborate 
evidence on the clinical effi cacy of entacapone from earlier trials: The daily ON-time was 
signifi cantly increased (by one hour or more), with a corresponding reduction in time 
spent in the “off” state (Table 4). Signifi cant improvement was also observable in PD dis-
ability scales such as the motor and Activities of Daily Living (ADL) subscores of the UPDRS 
(10, 11, 248). ADL and quality of life-related parameters seem to improve also in clinically 
non-fl uctuating patients (Table 4) (248–250).
The clinical benefi ts of entacapone are achieved and sustained despite a 10 to 30% 
reduction in the total daily dosage of L-dopa (10, 170, 251). Its clinical effects are also 
achieved from the fi rst dose (204) and are sustained during long-term therapy for up to 
at least 3 years (10, 11, 251).
Table 4. Benefi cial effects of entacapone as an L-dopa adjunct (258).
Patient group Effect
L-dopa-treated, motor fl uctuations Increased ON-timea
Decreased OFF-timeb
Reduced L-dopa dosage
Modestly improved UPDRS motor and ADL scores
L-dopa treated, without motor fl uctuations Improved UPDRS ADL scores
Improved QoL scores
Reduced L-dopa dosage
Improved UPDRS motor scores (some studies)
L-dopa naïve (de novo) Not yet assessed
a period when mobile or capable of moving with relative ease; b period when immobile or in-
capable of moving with relative ease.
UPDRS, Unifi ed Parkinson’s disease Rating Scale; ADL, Activities of Daily Living; QoL, Quality 
of Life.
Entacapone improves the clinical response to L-dopa regardless of the type of L-dopa 
formulation (standard or CR), the DDC inhibitor (158, 243, 244, 248, 252), or the con-
comitant use of a DA agonist or selegiline or both (10, 11, 248, 249, 253).
A triple combination (TC) tablet consisting of L-dopa, carbidopa (in 4:1 ratio, respec-
tively), and 200 mg entacapone (StalevoTM) has recently become available. TC comes in 
three strengths, which are bioequivalent to corresponding doses of L-dopa/carbidopa and 
entacapone administered separately.
No conclusive evidence is available on the effi cacy of entacapone in de novo PD pa-
tients. It has been suggested that pulsatile stimulation of striatal DA receptors by short-
acting agents (like L-dopa) may have deleterious effects by inducing motor response com-
plications (117). Drugs that provide more continuous dopaminergic stimulation could 
therefore prove more benefi cial (254). As COMT inhibitors can attenuate “peak-trough” 
variations in plasma L-dopa levels (204, 206), they might, if instituted early, be able to 
provide some benefi ts of continuous dopaminergic stimulation, meaning postponement 
of L-dopa-related motor complications (110, 255). Although these notions are supported 
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by some recent animal data (256, 257), clinical evidence is lacking. One study assessing 
the effects of early introduction of entacapone on emergence of L-dopa-related motor 
complications (STRIDE-PD) is currently underway.
Clinical safety experience
Entacapone has been well tolerated, with a good long-term safety profi le, also in com-
bined use with other antiparkinsonian agents like DA agonists, selegiline, amantadine, 
and anticholinergics (10, 11, 251, 259). Its discontinuation rate has not signifi cantly dif-
fered from that during placebo (251, 259).
The clinically relevant AEs of entacapone therapy have been reviewed (170, 260), and 
those that occur signifi cantly more frequently with entacapone than with placebo are 
listed in Table 5.
As a result of enhanced brain entry of L-dopa, entacapone may aggravate or induce 
dopa-related AEs, especially dyskinesia (10, 11, 248, 251, 259). This occurs almost exclu-
sively during the fi rst days or weeks after initiation of therapy (10, 11, 170, 248, 259), 
and particularly in those with a previous history of dyskinetic movements (157, 158, 170, 
261). Dyskinesia can be largely controlled by reducing the total daily dosage of L-dopa 
(extension of dosing interval or lowering of individual doses) (170, 204, 234, 239, 248). In 
patients at risk (pre-existing dyskinesia, high L-dopa dosage), pre-emptive measures may 
be warranted, such as reducing L-dopa dosage at the time of initiation of entacapone 
(158, 170). Nausea usually appears soon after introduction of entacapone therapy (170, 
260). Psychic dopaminergic AEs are quite rare. All dopaminergic AEs respond favorably 
to L-dopa dosage reductions.
Table 5. Adverse events of entacapone in long-term placebo-controlled studies, adapted 
from (158).
Adverse event Entacapone (n=806) % Placebo (n=497) %
Dopaminergic
   Dyskinesia/hyperkinesia 30.4*** 17.5
   Nausea 13.6*** 17.4
   Vomiting 13.6** 11.2
Non-dopaminergic
   Urine discoloration 10.8*** 10.0
   Diarrhea 10.3*** 13.8
   Abdominal pain 17.3* 14.2
   Constipation 17.2* 14.2
   Fatigue 16.1* 13.6
*, p<0.05; **, p<0.01; ***, p<0.001 (entacapone vs. placebo).
Gastrointestinal AEs (diarrhea, constipation, abdominal pain) occur signifi cantly more fre-
quently with entacapone than with placebo (10, 11, 170, 248, 260), but their emergence 
may be delayed until several weeks or months into therapy. A non-dangerous phenom-
enon encountered when using either entacapone or tolcapone is dark yellow/reddish-
brown discoloration of the urine (10, 157, 234, 253, 262).
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In contrast to entacapone, tolcapone can induce severe dyskinesia (12, 13). It also 
demonstrates a higher discontinuation rate due to diarrhea, which may be explosive 
(12).
Cases of fatal liver failure due to tolcapone therapy have numbered three (263, 264), 
resulting in a temporary suspension of its marketing authorization in the EU region. Its 
propensity to form reactive intermediates and to interfere with mitochondrial energy pro-
duction has been proposed as an explanation for its hepatotoxic potential (265, 266). As 
for entacapone, clinical trials and post-marketing surveillance studies have demonstrated 
no increase in liver enzyme levels above those observed with placebo, with no treatment-
related cases of acute liver failure or death (157, 158, 259, 267). During entacapone 
therapy, routine monitoring of liver function is unnecessary (158, 170).
Abrupt withdrawal of antiparkinsonian medication has sometimes been associated 
with neuroleptic malignant-like syndrome (NMS) and rhabdomyolysis (264). There is one 
case report of the emergence of NMS after abrupt withdrawal of tolcapone (268). So far, 
no such cases have been reported to occur after withdrawal of entacapone.
2.3.6. COMT inhibition and cardiovascular autonomics in PD
The high capacity of COMT has therapeutic relevance in respect to both the effi cacy and 
safety of COMT-inhibitor treatment. It has been suggested that only a minor fraction of 
the capacity of the enzyme is ever needed (14), which implies that although substantial 
COMT inhibition with signifi cant pharmacodynamic effects is achievable in patients with 
PD, the remaining COMT activity should still be capable of eliminating naturally occurring 
catecholamines. The level of COMT inhibition achieved by nitrocatechol compounds is 
far from complete. Nitecapone, as one example, is able to reduce COMT activity by 50 to 
60%, but not much more despite substantial increases in its dosage (229).
Catecholamine metabolism
In theory, therapeutic inhibition of COMT could increase plasma levels of endogenous 
catecholamines (especially during physical exercise, when their release is markedly aug-
mented) or of the exogenous catechol-structured compounds that are substrates of the 
enzyme. However, the reported effects of the nitrocatechol COMT inhibitors nitecapone 
and entacapone on plasma catecholamine (DA, NA, and adrenaline) levels in healthy hu-
mans have consistently shown that such an increase does not occur, and that both rest-
ing and exercise plasma levels of unconjugated (free) catecholamines remain unchanged 
after both single and repeated dosing of either nitecapone (up to 100 mg t.i.d.) or en-
tacapone (up to 800 mg t.i.d.) (16, 17, 269–271). An equally consistent fi nding in these 
studies has, however, been the altered metabolic profi le of catecholamines caused by 
these COMT inhibitors. They have been shown to reduce plasma levels of methylated 
(COMT-dependent) metabolites of catecholamines (156). Levels of MAO-dependent me-
tabolites have increased accordingly. Some of the changes in catecholamine metabolism 
are dose-dependent (17, 242). Changes in other pathways of catecholamine metabolism, 
for instance conjugation, also occur (270).
In healthy volunteers, following single or multiple dosing of either nitecapone or en-
tacapone, an altered metabolic profi le of peripheral DA has been evident in signifi cantly 
increased plasma levels of DOPAC (Fig. 1) and decreased urinary excretion of HVA (17, 
269-271). Similar fi ndings emerged in healthy subjects receiving single doses of either 
nitecapone or entacapone as adjuncts to L-dopa/carbidopa. Their plasma DOPAC levels 
are markedly increased (228, 236, 242), whereas those of HVA are either decreased (228, 
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242) or remain unchanged (236). The urinary excretion of methylated metabolites of DA 
(3-methoxytyramine and HVA) also decreases (228). Similar changes in catecholamine 
metabolism have taken place in L-dopa-treated PD patients: After either single or mul-
tiple dosing of entacapone for up to one month, plasma DOPAC levels are signifi cantly 
increased, whereas plasma levels and urine excretion of HVA are somewhat decreased 
(232, 235, 240).
Changes also occur in the metabolic profi le of NA and adrenaline. Plasma levels of 
3,4-dihydroxyphenylethylene glycol (DHPG, a MAO-dependent metabolite of NA and 
adrenaline, Fig. 1) have been markedly higher, and those of 3-methoxy-4-hydroxyphe-
nylethylene glycol (MHPG, a COMT-dependent metabolite) lower after single or multiple 
dosing of either nitecapone (269, 270) or entacapone (16, 17, 271, 272). These changes 
have been suggested to be due to both shunting of the metabolism towards MAO-
catalyzed oxidation and, in the case of DHPG, for instance, inhibition of COMT-catalyzed 
methylation in the subsequent steps of the metabolic pathway (Fig. 1) (16). After niteca-
pone, changes in the profi le of urinary catechol metabolites, such as the reduced urinary 
excretion of 3-methoxy-4-hydroxymandelic acid and metanephrine have also occurred 
(228, 269). COMT inhibition seems to elevate plasma levels of some conjugated catecho-
lamines. After repeated administration of nitecapone, a three-fold increase in the plasma 
concentration of conjugated adrenaline has occurred (270).
Data are less concerning the effects of tolcapone on plasma catecholamines and their 
metabolites. Similar to the other two nitrocatechol COMT inhibitors, tolcapone as an 
adjunct to L-dopa has raised plasma DOPAC levels, and reduced those of HVA (230, 273). 
Effects of tolcapone on plasma HVA are more pronounced than are those of entacapone, 
probably due to its central COMT inhibitory action. Prolonged therapy in parkinsonian 
patients with tolcapone as an adjunct to L-dopa also signifi cantly elevates plasma levels 
of the actual catecholamines DA, NA, and adrenaline (273, 274).
In addition to the endogenous catecholamines, several catechol-structured drugs 
(adrenaline, isoprenaline, dobutamine, apomorphine) are substrates of COMT. In experi-
mental animal models, COMT inhibition potentiates the cardiovascular effects of exog-
enously administered catecholamines (275, 276). Against this background, a theoretical 
safety concern arises regarding possible drug-drug interactions between these agents. In 
one study, a single 400-mg dose of entacapone in healthy subjects did not signifi cantly 
change plasma concentrations of intravenously administered adrenaline or isoprenaline 
(277). Systemic clearances of these two catecholamines by either the intact fraction of 
COMT activity or other metabolic routes are likely explanations for these fi ndings.
Another concern is potential interaction between COMT inhibitors and other drugs 
having an effect on catecholamine turnover. In healthy humans, resting and exercise 
plasma levels of neither NA nor adrenaline were affected by the simultaneous inhibition 
of COMT by entacapone and of neuronal re-uptake by imipramine (272). Similar fi ndings 
have resulted from co-administration of desipramine and tolcapone (278).
Hemodynamics and cardiac rhythm
Clinical evidence has, thus far, consistently shown that single or multiple administration 
of either nitecapone (up to 100 mg t.i.d.) or entacapone (up to 800 mg t.i.d.) to healthy 
subjects does not change rest/exercise hemodynamics or cardiac rhythm (16, 17, 269-
272). In L-dopa-treated patients with PD, resting hemodynamics has not been affected by 
single or multiple dosing of entacapone (232, 234, 235). Although a more pronounced 
orthostatic drop in systolic BP has occurred after entacapone than after placebo (240), 
this has been clinically non-signifi cant, and in parkinsonian patients, orthostatic hypoten-
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sion itself has seldom been a problem during entacapone therapy (170, 232, 240). In 
phase III studies, manifestations of orthostatic hypotension such as dizziness and falls 
have been equally frequent in the entacapone and placebo arms, with no differences in 
the supine and standing BP, HR, or ECG (10, 11, 248, 259).
Pharmacodynamic interactions between COMT inhibitors and some vaso-/neuroac-
tive drugs infl uencing hemodynamics and cardiac rhythm have also been investigated in 
healthy human subjects. Pressor response to intravenously administered tyramine has not 
been enhanced by nitecapone (279). Similarly, entacapone does not signifi cantly change 
BP response to either isoprenaline or adrenaline infusions (277), but the chronotropic 
effect of isoprenaline is potentiated, with caution advised in considering the use of enta-
capone with any exogenous catecholamines that are substrates of COMT (277).
Hemodynamic effects of COMT inhibition have also been studied in a subset of MSA 
patients with profound autonomic involvement. In contrast to PD, entacapone dose-de-
pendently increases the systolic BP in MSA patients (without any changes in plasma levels 
of DA, NA, or adrenaline) (280). In addition, the systolic BP response to phenylephrine 
during COMT inhibition was ten-fold higher than that of healthy controls. One sugges-
tion is a particular susceptibility of MSA patients to the hemodynamic effects of COMT 
inhibition due to their impaired barorefl ex function and vascular NA hypersensitivity in 
contrast to that of healthy controls and PD patients with intact autonomic function. An 
additional hypothesis is the predominant effect of COMT inhibition on synaptic rather 
than on circulating NA turnover.
No interactions related to hemodynamics or cardiac rhythm were reported in healthy 
humans during combined use of entacapone plus imipramine (272) or tolcapone plus 
desipramine in conjunction with L-dopa/carbidopa (278). The chronotropic effect of these 
re-uptake inhibitors is not enhanced by concomitant COMT inhibition. Based on the clini-
cal data available, no clear hemodynamic interaction between entacapone and either 
tricyclic antidepressants or serotonin uptake inhibitors has occurred in patients with PD 
(267).
Parameters of cardiovascular autonomic function
Few studies with small numbers of patients implement a rigorous assessment of the 
effects of COMT inhibitors on cardiovascular autonomic responses in PD. In one open 
randomized, cross-over study with eight patients, cardiovascular autonomic responses to 
sympathetic or parasympathetic stimuli were unchanged by a single dose of entacapone 
200 mg given as an adjunct to L-dopa (235). Parameters of HR variation determined from 
24-hour ambulatory ECG recordings were not changed after 6-month therapy with tol-
capone in conjunction with L-dopa in seven patients with PD (281).
Co-inhibition of COMT and MAO enzymes
Anecdotal reports are available on clinically signifi cant drug-drug interactions between 
selegiline and some catecholamines and their uptake inhibitors (Section 2.2.2.). Cardio-
vascular safety aspects of the simultaneous inhibition of MAO-B and COMT enzymes 
have not yet been studied much in humans. In theory, for several reasons co-inhibition 
of these two enzymes should not compromise cardiovascular function: First, neuronal 
re-uptake is the principal peripheral route of inactivation of endogenous catecholamines, 
and metabolic pathways like COMT and MAO play only a supplementary role: Second, 
the peripheral COMT pool is only partially inhibited by these nitrocatechol compounds, 
leaving substantial enzymatic activity intact: Third, at the dosages used in the treatment 
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of PD, selegiline is highly MAO-B selective. Because this subtype of MAO is almost ex-
clusively localized in the central nervous system, selegiline should not contribute to the 
turnover of peripheral catecholamines.
According to one report involving PD patients chronically treated with selegiline and L-
dopa, acute administration of tolcapone up to doses of 800 mg was well tolerated, with 
no cardiovascular adverse effects (282). The effects of simultaneous inhibition of COMT 
by entacapone and MAO subtype A (MAO-A) by moclobemide has been investigated in 
healthy subjects, both at rest and during enhanced catecholamine release (exercise). In 
contrast to MAO-B, MAO-A predominates in the peripheral tissues. However, the com-
bined use of entacapone and moclobemide in single therapeutic doses has no effect on 
plasma levels of free catecholamines, BP, HR, or ECG, when compared to the use of either 
drug alone, or to the use of placebo (271).
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3. AIMS OF THE STUDY
The main purpose of the present study was to evaluate – in a double-blind, placebo-
controlled setting – the safety profi le of the COMT inhibitor entacapone after repeated 
dosing with the drug as an L-dopa adjunct to patients with PD. The more specifi c aims 
were:
1. Evaluation of the cardiovascular safety of entacapone
• during simultaneous administration with selegiline by using repeated measure-
ments of hemodynamics, ECG, and plasma catecholamine levels (I, II)
• by investigating its effects on cardiovascular autonomic function (III)
• by studying its effects on cardiorespiratory exercise performance (IV)
2. Evaluation of the clinical effi cacy and tolerability of the simultaneous administration 
of entacapone and selegiline by use of repeated assessments of motor disability, dys-
kinesia, and ambulatory motor activity (I, II).
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4. SUBJECTS AND METHODS
4.1. Subjects
A total of 39 patients with idiopathic PD were investigated in three clinical studies. The 
characteristics of their disease met the main clinical diagnostic criteria of the United
Kingdom PD Society Brain Bank (81). Characteristics of the patients are summarized in 
Table 6.
The clinical severity of PD in the study population was either mild or moderate (stages 
I–III) according to modifi ed H&Y staging (79). The patients used L-dopa as their main an-
tiparkinsonian therapy and were all L-dopa responders. The major inclusion and exclusion 
criteria and distribution of individual patients are presented in Tables 7 and 8.
Table 6. Characteristics of 39 Parkinson’s disease patients in the studies of entacapone.
Study No. (Publication)
Characteristics First (I) Second (II) Third (III & IV)
Number of subjects 13 16 15
Women / Men 6 / 7 4 / 12 4 / 11
Age (years)1  65 ± 8 1.63 ± 8 .157 ± 8
Weight (kg)1 NA 1.71 ± 11 .174 ± 10
Height (m)1 NA 1.69 ± 0.09 1.71 ± 0.10
Duration of PD (years)1 .5.5 ± 5.2 14.6 ± 4.4 15.8 ± 3.4
Duration of L-dopa therapy (years)1 .4.4 ± 3.3 13.8 ± 3.3 15.3 ± 2.6
Duration of fl uctuations (years)1 .2.2 ± 2.0 11.9 ± 2.4 12.8 ± 1.53
Total daily L-dopa dose (mg)1 723 ± 101 .722 ± 160 .720 ± 160
Hoehn & Yahr (n)2
Stage 1
Stage 1.5
Stage 2
Stage 2.5
Stage 3
–
–
10
–
3
5
–
10
–
1
1
3
10
1
–
1 Mean ± SD (when applicable); 2 Hoehn & Yahr stage determined during ON-state; 3 Includes 
those with motor fl uctuations (N=12); PD, Parkinson’s disease; NA, not available.
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Before entering either the fi rst or second study, any patient using CR L-dopa was switched 
at the time of recruitment to approximately equivalent dosage of a standard-release 
preparation. This new dosage was then gradually adjusted to achieve satisfactory clinical 
benefi t. Upon entering the fi rst study, all patients were taking L-dopa/benserazide t.i.d or 
q.i.d. (mean = 3.6 doses/day). In the second study, either L-dopa/benserazide (n=13) or 
L-dopa/carbidopa (n=3) was used in 3 to 5 daily doses (mean = 3.4 doses/day). In the third 
study, patients used standard-release (n=5), CR (n=4), or both (n=6) preparations in 3 to 
5 daily doses (mean = 3.3 doses/day). However, CR was taken only at night. Although 
dosages of all antiparkinsonian drugs were to remain unchanged throughout the studies, 
clinically indicated (such as for marked dyskinesia) adjustments in L-dopa dosage were 
allowable.
In general, no drugs that could adversely interfere with either the conduct or the 
assessment of responses in the studies (DA receptor-antagonists, antiarrhythmic drugs) 
were allowed (Table 7), and use of such drugs was prohibited throughout the course of 
the studies.
Table 7. Major inclusion and exclusion criteria in studies 1–3.
Inclusion criteria
Applies
to study
Clinically mild-moderate Parkinson’s disease (Hoehn & Yahr stages I–III) All
End-of-dose (“wearing-off”) -type motor response fl uctuations 1,2
Either stable or fl uctuating response to L-dopa 3
Standard- (immediate-) release L-dopa/DDC inhibitor 1,2
Standard- (immediate-) and/or controlled release L-dopa/DDC inhibitor 3
Stable daily dosage of L-dopa for ≥1 month All
Stable (for ≥1 month) dosage of a dopamine agonist, amantadine,
or anticholinergic, if used
All
Exclusion criteria
Clinically severe Parkinson’s disease (Hoehn & Yahr stages IV–V) All
Stable motor response to L-dopa (“non-fl uctuator”) 1,2
Marked/disabling on-period dyskinesia All
Random (“on-off”) motor response fl uctuations All
Clinically signifi cant and/or unstable co-morbid (e.g., cardiovascular,
pulmonary, renal, hepatic, psychiatric) state
All
Use of selegiline (<1 month prior entering the study) 1,2
Recent (<1 month) use of dopamine receptor blocking agents
(e.g. neuroleptics and their anti-emetic derivatives) 
All
Recent (<1 month) use of monoamine-oxidase (MAO) inhibitors
(either non-selective or MAO-A selective)
All
Recent (<1 month) use of tricyclic antidepressants (e.g., amitriptyline) 1
Use of sympathomimetics (α-/β-receptor agonists) All
Use of certain antiarrhythmic/-hypertensive drugs (e.g., digitalis,
ACE-inhibitors, Ca-channel blockers, α-/β-receptor antagonists) 
All
DDC, dopa decarboxylase; ACE, angiotensin converting enzyme.
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Table 8. Distribution of the patients with Parkinson’s disease in studies 1–3.
Duration of
Subject 
No.
Study 
No.
Age (years) / 
Gender
Weight (kg) /
Height (cm)
PD
(years)
L-dopa
therapy
(years)
Fluctuations
(years)1
H&Y
stage
Dopamine
agonist (mg)
1 1,2 72 / M 62 / 172 11 10 10 3
2 1 45 / F NA 8 5 3 2
3 1 75 / F NA 1 1 1 2
4 1 71 / F NA 1 1 1 2
5 1 65 / F NA 4 4 1 2
6 1 76 / F NA 2 1 1 2
7 1 68 / M NA 2 2 1 2
8 1,2 58 / M 70 / 182 3 3 1 2 Pergolide (3)
9 1,2 71 / M 74 / 172 7 7 5 2
10 1 65 / F NA 6 6 4 3
11 1,2 58 / M 73 / 170 3 3 1 2
12 1 62 / M NA 7 5 3 2
13 1 66 / M NA 20 12 1 3 Bromocriptine (20)
14 2 57 / M 54 / 165 1 1 1 1.5
15 2 58 / M 72 / 173 13 11 2 3
16 2 73 / F 57 / 158 1 1 1 2
17 2,3 62 / M 81 / 175 5 5 2 2
18 2 68 / F 52 / 152 2 2 1 2
19 2 56 / M 93 / 176 5 4 0 2
20 2 73 / F 66 / 157 5 4 1 2
21 2 66 / F 74 / 156 2 1 1 1
22 2 47 / M 75 / 176 1 1 1 1
23 2 59 / M 82 / 176 1 1 1 1.5
24 2 68 / M 67 / 175 14 7 2 1.5 Bromocriptine (30)
25 2 60 / M 80 / 175 1 1 1 2
26 3 43 / F 63 / 167 6 6 2 2 Pergolide (1.5)
27 3 56 / M 74 / 165 8 8 6 2
28 3 60 / F 71 / 166 8 7 NF 1.5 Bromocriptine (15)
29 3 60 / F 58 / 154 9 8 NF 2
30 3 56 / M 73 / 164 1 1 NF 1.5
31 3 46 / M 90 / 183 6 6 4 2 Bromocriptine (30)
32 3 48 / M 70 / 171 3 3 2 2 Bromocriptine (30)
33 3 60 / M 71 / 173 2 1 1 1
34 3 61 / M 67 / 171 2 2 1 2 Bromocriptine (15)
35 3 49 / M 87 / 186 5 5 2 2 Bromocriptine (20)
36 3 69 / M 79 / 168 6 6 3 2.5
37 3 47 / M 82 / 178 5 5 5 2
38 3 65 / F 60 / 156 6 6 2 1.5
39 3 63 / M 85 / 185 15 10 3 2
In the fi rst and second studies selegiline was prohibited for one month before and throughout the study, whereas in the 
third study it was used by every patient in doses of either 5 (n=4) or 10 (n=11) mg o.d. The total daily doses for dopamine 
agonists are given. None of the patients were on amantadine or anticholinergic therapy. PD, Parkinson’s disease; H&Y, 
Hoehn & Yahr; F, female; M, male; NA, not available; NF, non-fl uctuator; 1end-of-dose (wearing-off) type fl uctuations.
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4.2. Methods
4.2.1. Design of the studies
Treatment comparisons and course of the studies
Each study was approved by the Ethics Committee of the Department of Neurology, Hel-
sinki University Central Hospital, Helsinki, Finland, and conducted in accordance with the 
guidelines of the amended Declaration of Helsinki. After being provided with oral and 
written information on the study objectives, design, and possible risks and discomforts 
involved, the patients gave their written informed consent.
All the studies were preceded by similar screening procedures, which included a gen-
eral physical examination, assessment of supine/standing BP and HR (Section 4.2.2.), ECG 
(Section 4.2.2.), sampling of venous blood and urine for laboratory safety tests (Section 
4.2.6.), and assessment of motor disability (Section 4.2.7.).
In the third study, screening also included determination of forced vital capacity (FVC), 
forced expiratory volume during one second (FEV1), FEV% (=FEV1/FVC), peak expiratory 
fl ow, maximal expiratory fl ow at 25% and at 50% of FVC, and maximal mid-expiratory 
fl ow by use of fl ow-volume spirometry, and comparison of results with the reference 
values of Viljanen (283). Direct maximal voluntary ventilation was also calculated. The 
results of all screening investigations were available before patients were enrolled into 
the studies.
All three studies were of double-blind, placebo-controlled, crossover design (Fig. 4), 
and patients were randomly allocated to study treatments (Table 9). The randomization 
procedure was carried out by the Unit of Biostatistics and Data Management, Orion Phar-
ma, Espoo, Finland, using specifi c software.
Table 9. Treatments contrasted in the three studies.
Study Comparators Fixed treatments
First a)  Selegiline 10 mg o.d. Entacapone 200 mg with each dose of 
L-dopa/DDC inhibitor (3–4 daily doses)
b)  Placebo o.d.
Second a)  Selegiline 10 mg o.d. L-dopa/DDC inhibitor (3–4 daily doses)
b)  Entacapone 200 mg (× 3–4)
c)  Selegiline 10 mg o.d. +
c)  Entacapone 200 mg (× 3–4)
Third a)  Entacapone 200 mg (× 3–5) L-dopa/DDC inhibitor (3–5 daily doses)
b)  Placebo (× 3–5)
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The duration of each treatment period was either one (third study) or 2 weeks (fi rst 
and second study). The fi rst study included a 2-week washout (no selegiline) between 
treatments; in the second, there were two 4- to 8-week washouts (no entacapone or 
selegiline), one between each two treatment periods (Fig. 4). The third study included no 
washouts.
Course of the study visits
The main assessments were conducted during study visits (Fig. 4). Within each study, the 
general course of all study visits was identical. The fi rst (control) visit was held prior to 
any study treatment, serving as a baseline, open-label assessment of L-dopa response in 
the fi rst and second studies (Section 4.2.7.). In the third study, assessments during the 
control visit were performed after overnight withdrawal of L-dopa (practical off-state). 
During the remaining study visits the assessments were done in a timely manner after the 
administration of the study treatments with the morning dose of L-dopa. The study visits 
were conducted at the Outpatient Department of Neurology, Helsinki University Central 
Hospital, Helsinki (fi rst and second study), whereas the function tests of cardiovascular 
autonomics (Section 4.2.3.) and the exercise tests (Section 4.2.4.) of the third study were 
performed in the Laboratory of Clinical Physiology and Nuclear Medicine, Helsinki Univer-
sity Central Hospital, Helsinki.
Study visits were each preceded by a 24-hour ambulatory (Holter) ECG (second and 
third study, Section 4.2.2.) and activity (actigraphy, fi rst and second study, Section 4.2.8.) 
recordings.
The course of the study visits is described in Table 10. The patients refrained from tak-
ing their morning antiparkinsonian medication at home before arriving at the hospital. 
After arrival, the Holter (second study) and Actigraph (fi rst and second study) devices 
were detached, and an intravenous catheter was inserted in the antecubital vein for 
blood sampling (fi rst study).
After baseline assessments of the fi rst and second studies, an L-dopa test was carried 
out. Appropriate study drugs were administered at 8 a.m., and the patients were then 
followed for 6 hours. The follow-up included repeated assessments of clinical (Section 
4.2.7.) and hemodynamic (BP and HR) parameters (Table 10). In the fi rst and second 
studies, the patients also self-evaluated their sleep, using a specifi c sleep questionnaire 
(Section 4.2.8.) supplementary to the ambulatory activity monitoring. The next doses 
of antiparkinsonian drugs were allowed at 2 p.m., the time of their departure from the 
hospital.
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The study visit schedule of the third study was rather different (Table 10). It included 2 
consecutive days of assessment with an ambulatory ECG registration (Holter) in between. 
On day 1, the patients arrived at 8:45 a.m., and the study medication (omitted from the 
control visit) was administered at 9 a.m. On day 2, the patients arrived at 10:45 a.m. The 
Holter device was detached, and the study drugs were administered at 11 a.m. (but not 
on the control visit). On either day 1 or 2, the patients were forbidden to take dopamin-
ergic drugs other than the study medication (DA agonists, selegiline) prior to the tests. 
On day 1, tests of cardiovascular autonomic function (Section 4.2.3.) were performed, 
followed by a maximal work-conducted exercise test (Section 4.2.4) on day 2.
Within the fi rst and second studies were also several short safety visits to the Out-
patient Department (see original publications for details). These occurred during each 
treatment period shortly after initiation of study therapy, during washouts, and post-
study. During safety visits, a modifi ed motor UPDRS was rated, and supine/standing BP 
and HR, ECG, AEs, and (during certain visits) blood safety parameters were assessed. The 
investigators were also entitled to make adjustments to the L-dopa dosage, if clinically 
indicated.
Table 10. Course of the study visits.
Time: h 8 9 10 11 12 13 14
min bl .30 .30 .30 .30 .30 .30
Study
DRUG INTAKE 1,2 X
  - “ - 3 Xa Xb
ASSESSMENTS (Section)
Biochemistry (4.2.6.)
 Blood & urine safety 1,2 X
   - “ - 3 Xc
 L-dopa & entacapone PK 1 X X X X X X X X
 3-OMD 3 Xc
 Catecholamines 1 X X
 Plasma noradrenaline 3 Xc Xc
 S-COMT activity 1 Xc
 MAO-B activity 1 X
Cardiovascular & respiratory
 Supine/standing BP & HR (4.2.2.) 1,2 X X X X X X X
 ECG (4.2.2.) 1,2 X X
 ECG (4.2.4.) 3 Xb Xb
 Cardiovascular autonomicsa (4.2.3.) 3 X----------------------------X
 Cardiorespiratory exerciseb (4.2.4.) 3 X------------X
 Maximal airway pressures (4.2.5.) 3 Xb
Clinical
 Modifi ed motor UPDRS (4.2.7.) 1,2 Xd X X X X X X X X X X X X
   - “ - 3 Xb Xb
 AIMS (4.2.7.) 2 X X X X X X X X X X X X X
 Adverse event questioning (4.2.9.) 1,2 X X
   - “ - 3 Xa Xb Xb
bl, baseline assessments (before drugs); PK, pharmacokinetics; 3-OMD, 3-O-methyldopa; S-COMT, soluble 
catechol-O-methyltransferase; MAO-B, monoamine oxidase type B; BP, blood pressure; HR, heart rate; 
UPDRS, Unifi ed Parkinson’s Disease Rating Scale; AIMS, Abnormal Involuntary Movement Scale. aday 1 of 
study visits; bday 2 of study visits; cnot assessed during control visit; dscored twice in study 1.
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4.2.2. Assessment of cardiac rhythm and hemodynamics
Responses to L-dopa test: blood pressure, heart rate, ECG
Both the schedule and the methods for assessment of hemodynamic variables and ECG 
were similar in the fi rst and second studies. Supine and standing BP and HR were meas-
ured after 5 minutes of rest and 3 minutes of standing (bedside orthostatic test), respec-
tively, fi rst before drug intake (baseline) and then once per hour for 6 hours following 
administration of study drugs. The device used in the measurements (Omron BP monitor 
HEM 706) was calibrated at Orion Pharma, Espoo, Finland. It applied an oscilloscopic 
method of assessment and gave a digital read-out of the variables. Mean daily values for 
both supine and standing systolic BP, diastolic BP, and HR during each study visit were 
calculated from the consecutive measurements (n=7) of each visit. Changes in systolic BP, 
diastolic BP, and HR during each orthostatic test were calculated by subtracting supine 
values from values during standing. Mean daily changes in these variables were calcu-
lated as the mean of the differences (n=7) between standing and supine values during 
each study visit.
ECG was recorded before drug intake at 8 a.m. (baseline) and then at 9:30 a.m. 
(+1.5 hours from drug intake) in both studies. The recording was performed at rest from 
12 standardized leads (bipolar limb I, II and III; unipolar limb aVR, aVL and aVF; unipolar 
chest V1–V6) using self-adhesive electrodes. The method (recording device manufactured 
by Siemens) included automated procedures for calibration before each recording and a 
computer-assisted analysis of rate, rhythm, and conduction times (PQ and QT intervals 
and QRS duration). However, all these variables were also determined manually (by J.L.) 
from the ECG printouts.
Ambulatory ECG
All visits (second study) and day 2 of the second and third visits (third study) were pre-
ceded by continuous 24-hour ambulatory ECG (Holter) recording (284). For that purpose, 
the patients arrived at the Outpatient Department on the previous mornings for the 
mounting of the device (Marquette®). The registration was performed by directly record-
ing the 2-channel ECG signal through bipolar leads using self-adhesive skin electrodes 
(four recording, one ground) placed in inferior- and V5-like positions. The waist-worn 
recording unit was programmed for automatic calibration, and the data was stored in 
standard C-cassettes. The patients were instructed to keep a log of the quality and timing 
of any symptoms experienced during recording and also to press a specifi c event-trigger 
on the device whenever such a symptom would occur. The device was detached, and the 
patient logs were collected on the following morning upon their arrival at the Outpatient 
Department.
Analysis of the recordings was carried out by a qualifi ed cardiologist (Dr. J. Partanen) 
from the Department of Medicine, Helsinki University Central Hospital, using a semi-au-
tomated ambulatory ECG analysis system manufactured by Marquette. Variables of inter-
est were the occurrence of supraventricular extrasystoles (SVES, beats/hour), ventricular 
extrasystoles (VES, beats/hour), ventricular tachycardias (number of runs per recording), 
and also the mean HR during recording (HRmean, beats/min).
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4.2.3. Cardiovascular autonomic responses
During each study visit in the third study, patients were subjected to cardiovascular refl ex 
testing initiated 60 min after administration of the study drugs. This test was performed 
in a sound- and temperature-controlled (ambient temperature a constant 24°C) environ-
ment at the Laboratory of Clinical Physiology. A battery of four tests of cardiovascular 
autonomic function, all based on measuring of BP and HR responses to appropriate stim-
uli, was performed according to established methods (47, 285). The tests were a deep 
breathing test, an orthostatic test, Valsalva’s maneuver, and a sustained (isometric) hand-
grip test. These tests are considered to be simple to perform in a clinical setting (286).
The primary method of assessment in the fi rst three tests was to measure HR varia-
tion (HRV) in response to maneuvers that change vagal (parasympathetic) or sympathetic 
outfl ow to the heart or both. In practice, this was accomplished by manually measuring 
R-R interval variation from 12-lead ECG strips recorded during the tests. BP responses 
– which additionally refl ect sympathetic outfl ow to blood vessels – in the orthostatic and 
hand-grip tests were recorded manually with a non-invasive intermittent cuff and aneroid 
manometer, and with auscultation of Korotkoff sounds I and IV.
In addition to statistical comparison of continuous variables from each test (Section 
4.3.2.), responses were dichotomously categorized as either normal or pathologic, based 
on age-related reference values from a healthy Finnish population (287). In the evaluation 
of orthostatic hypotension, consensus criteria for its defi nition were either a ≥20 mmHg 
decrease in systolic or ≥10 mmHg decrease in diastolic BP or both during 3 minutes of 
standing (288).
Deep breathing test
In the fi rst test of cardiovascular autonomic function, HRV was studied in response to 
deep breathing. A 12-lead ECG was continuously recorded while the patients, lying su-
pine, were instructed to take deep breaths at a rate of six breaths/min (10 seconds per 
respiratory cycle), a rate found to produce maximum HRV (289). A study nurse used ver-
bal cues to pace the effort. The shortest (inspiratory) and longest (expiratory) R-R intervals 
corresponding to six consecutive respiratory cycles were manually measured (by J.L.) from 
the ECG tracings. Values for R-R interval (mm) were transformed to HR (beats/min) by 
the formula HR = 1500 / RR interval. The mean of differences was calculated between 
maximum and minimum HR in each cycle (deep breathing difference).
Orthostatic test
In the second test of autonomic function, cardiovascular responses to active standing 
were studied in a 3-minute orthostatic test. BP was fi rst measured and ECG recorded 
after 10 minutes of quiet, supine rest. The patients were then asked to stand up abruptly 
from a supine position. During the 3 minutes of standing, with feet placed slightly apart 
and without external support, ECG tracings were recorded, fi rst continuously for 30 sec-
onds and then in 10-second strips at 30-second intervals. BP and HR (from ECG) were 
determined after one and 3 minutes of standing. During the test, the patients were 
observed for abnormal signs, and after its completion they were queried as to whether 
AEs had occurred during the test. The symptoms specifi cally asked about were vertigo, 
dizziness, fatigue, tremor, sweating, and palpitation.
The changes in systolic (∆SBP3–0min, mmHg) and diastolic (∆DBP3–0min, mmHg) BP dur-
ing the orthostatic test were calculated by subtracting the corresponding supine values 
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from those measured after 3 minutes of standing. The changes in HR after one (∆HR1–0min, 
beats/min) and 3 minutes (∆HR3–0min, beats/min) of standing were calculated accord-
ingly. The presence or absence of orthostatic hypotension was evaluated according to 
the recent consensus criteria described above (288). The hemodynamic reaction or joint 
changes in BP and HR after 3 minutes of standing were also categorized as either normal, 
vasovagal, hypoadrenergic or hyperadrenergic according to Appenzeller and Oribe (286). 
After manual measurement of the shortest (R-Rmin) and the longest (R-Rmax) R-R intervals 
from ECG tracings during the fi rst 30 seconds of standing, the corresponding maximum 
(HRmax = 1500 / R-Rmin) and minimum (HRmin = 1500 / R-Rmax) HRs, and their ratio (HRmax/
HRmin) were calculated.
Valsalva test
The third test was the Valsalva maneuver performed with the patients seated and con-
nected to an ECG recorder. Each was asked to take a deep breath and then blow into 
a resistive mouthpiece connected to a mercury manometer, maintaining 40 mmHg (5–6 
kPa) airway pressure for 15 seconds (290). A small air leak in the mouthpiece prevented 
closure of the glottis. A nose clip was also applied. ECG recordings were started 15 sec-
onds before, and continued until 30 seconds after releasing the strain. Corresponding 
time points were marked on the tracings. Three maneuvres were performed in succes-
sion, and the patients rested for 2 minutes between each two attempts. Valsalva ratios 
were calculated from the longest (phase IV) and the shortest (phase II) R-R intervals that 
were manually measured from the tracings by the investigator (J.L.) using an ECG ruler. 
The mean of the three ratios was calculated.
Isometric hand grip test
Before the isometric hand grip test, the maximum voluntary contraction (MVC) of each 
hand was measured with a calibrated analogue handgrip dynamometer. The hand with 
the higher MVC (best of three efforts) was selected for the test. Before the test the pa-
tients were coached how to maintain the effort, to breath regularly while avoiding the 
Valsalva maneuver. After a 5-minute rest, ECG and BP were recorded (baseline). The test 
was performed while seated, and the patients exerted a continuous force of 30% of their 
MVC on the dynamometer for 3 minutes. A study nurse monitored the dynamometric 
force for the whole duration of the test. BP and ECG were recorded at one-minute in-
tervals during and one minute after the test. If the patient was unable to complete the 
3-minute test, perhaps due to muscle pain or fatigue, BP and ECG were recorded at the 
time of termination.
The difference in diastolic BP between rest (baseline) and 3 minutes of effort (∆DBP, 
mmHg) was calculated.
4.2.4. Bicycle exercise test – cardiorespiratory responses
Course of the exercise test
On each study visit of the third study, a maximal work-conducted exercise test was per-
formed after either overnight withdrawal of L-dopa (control visit, “run-in” test) or 1.5 to 
2 hours after study drug intake (second and third study visits). For more details, see the 
methods in the original publication.
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The tests were performed with an electronically braked bicycle ergometer (Bosch) and 
an incremental workload (steady state) protocol with a 40-W starting load and 40-W 
increments (Fig. 5). Three-minute stages of constant work rate were chosen in order to 
achieve steady state for HR and gas-exchange kinetics (291).
Fig. 5. Protocol of the maximal work-conducted exercise test in the third study. A staged pro-
tocol (40 W increments, 3 minutes each) was applied. Repeated assessments of ventilatory 
gas-exchange parameters, ECG, blood pressure (BP), and rate of perceived exertion (RPE) were 
performed during each work stage. Each test (three per patient) was continued to subjective 
maximum (Wmax), if possible. The submaximal workload standard (Wstd = the highest com-
pleted work stage in all three tests) was determined for each patient individually. One example 
in Fig. 5: Wstd = 80W.
Before the test, an indwelling antecubital intravenous catheter was inserted, and blood 
was sampled (second and third visits) for determination of safety parameters and plasma 
3-OMD (Section 4.2.6.). The patients then rested supine for 30 minutes before blood 
sampling for plasma NA assay (Section 4.2.6.).
During the exercise test (Fig. 5), repeated measurements of BP were done, with con-
tinuous recording of ECG and capillary oxygen saturation. Cardiopulmonary auscultation 
was performed at the end of each work stage. The rate of perceived exertion (RPE) was 
evaluated at the end of each workload by use of Borg’s scale tables (292). With a mask/
mouthpiece, gas exchange samples were collected from expired air. The samples were 
driven through a pneumotachometer and a mixing chamber for continuous extraction 
into paramagnetic and infrared gas analyzers used, respectively for measurement of O2 
and CO2 partial pressures. Pneumotachometric spirometry was used in measuring breath-
ing frequency, tidal volume, and minute ventilation (VE) (EOS Jaeger, Erich Jaeger GmbH, 
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Würtzburg, Germany). Spiroergometric variables (Table 11) were automatically calculated 
at 30-second intervals. The test was continued to the subjective maximum (target RPE 
19–20/20), unless clinical criteria for discontinuation (293) were met. At peak exercise 
level, BP and ECG were recorded and blood was sampled for plasma NA assay (Section 
4.2.6.).
Table 11. Basic spiroergometric variables of Parkinson’s disease patients derived from a 
maximal bicycle ergometer test.
Variable Unit Explanation
Maximum work load (Wmax/3’) W Highest completed work load [W]
+ (duration at highest achieved work rate [min] / 3 min)
× 40 W
Breathing frequency (BF) 1/min Number of complete breaths per one minute
Tidal volume (VT) l, BTPS Volume of one breath
Minute ventilation (VE) l/min, STPD BF [1/min] × VT [l, BTPS] × 0,826
Fio2, FEo2 – Fractions of O2 in inspired and expired air, respectively
O2 uptake (Vo2) l/min, STPD VE [l/min, STPD] × (FIo2 - FEo2)
a
O2 pulse (Vo2/HR) ml/beat, STPD Vo2 [l/min, STPD] / HR [beats/min] × 1000 ml/l
FEco2 – Fraction of CO2 in expired air
CO2 output (Vco2) l/min, STPD VE [l/min, STPD] × FEco2
Respiratory exchange ratio (RER)b – Vco2 [l/min, STPD] / Vo2 [l/min, STPD]
Ventilatory equivalent for O2 – VE [l/min, BTPS] / Vo2 [l/min, STPD]
Ventilatory equivalent for CO2 – VE [l/min, BTPS] / Vco2 [l/min, STPD]
Breathing reserve % {(MVV [l/min] – VEmax [l/min]) / MVV [l/min]} × 100
W, watt; BTPS, gas volume at body temperature (37 °C) and pressure (47 mmHg) saturated 
with water vapor; STPD, gas volume at standard temperature (0 °C) and barometric pressure 
(760 mmHg), dry; O2, oxygen; HR, heart rate; CO2, carbon dioxide; MVV, maximal voluntary 
ventilation at rest; VEmax, minute ventilation at maximum exercise
ain dry room air; balso known as gas-exchange ratio (R) and respiratory quotient (RQ)
Blood pressure, heart rate, and ECG
Repeated manual measurements of BP (Fig. 5) were done with a brachial cuff, an aneroid 
manometer (Perfect Aneroid), and stethoscopic auscultation (Korotkoff sounds I and V) 
from the brachial artery. Systolic and diastolic BP were determined at peak (SBPmax and 
DBPmax) and submaximal exercise levels (SBPstd and DBPstd).
During exercise, ECG recording was done by simulated (Mason-Likar) 12-lead place-
ment (294) with continuous 6-channel ECG monitoring. Paper tracings were produced at 
30-sec. intervals. Analyses of HR, arrhythmias, ST-segment deviation (+ 0.06 sec. from J-
point), and ST/HR correlation for each lead were done automatically with a computerized 
ECG device (Case 12, Marquette Inc, U.S.A.). HR was determined at peak exercise (HRmax) 
and at submaximal exercise levels (HRstd).
Capillary oxygen saturation (Sao2)
Sao2 was monitored from the ear lobe throughout the exercise and the follow-up period 
with a pulse oximeter (Biox 3700, Ohmeda, U.S.A.). A drop in Sao2 of ≥3 percentage units 
from baseline (rest) or below the 90% level was considered clinically signifi cant. 
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Work capacity
The maximum workload (or power) achieved (Wmax/3’) for an incremental workload pro-
tocol was calculated according to Strandell´s formula (Table 11).
Ventilatory gas exchange variables
The between-treatment comparisons of the primary gas exchange variables (Table 11), 
namely O2 uptake (Vo2), O2 pulse (Vo2/HR), ventilatory equivalents for O2 (VE/Vo2) and CO2 
(VE/Vco2), and the breathing reserve, were carried out at two specifi c work rates: at peak 
exercise level, meaning at Wmax/3’, and at a specifi c submaximal exercise level (Wstd, see 
Fig. 5 and legend for details). Wstd was determined in order to control for the effect of 
work rate.
Vo2 is the amount of O2 extracted from inspired gas in any given period of time. 
The maximum O2 uptake (Vo2peak) represents the highest Vo2 achieved during presumed 
maximal exercise. Vo2peak can be calculated from the gas exchange data as the product of 
maximum minute ventilation (VEpeak) and the difference between the fractional amounts 
of O2 in the inspired (FIo2) and expired (FEo2) air (Table 11). Vo2 at submaximal exercise level 
(Vo2std) is determined accordingly.
O2 pulse is the amount of O2 extracted from the blood per stroke volume (SV). It can 
also be expressed as the product of SV and arteriovenous O2 difference [C(a-v)o2]. O2 
pulse is an index of cardiopulmonary capacity:
Vo2/HR [ml/beat] = SV × C(a-v)o2 × 1000 ml/l
O2 pulse can be calculated by dividing Vo2 [l/min, STPD] by HR [beats/min]. From the gas 
exchange data, O2 pulse at submaximal exercise level (Vo2/HRstd) was determined.
Ventilatory equivalents for O2 and CO2 (Table 11) are indices of ventilatory requirement 
needed in order to extract and eliminate any given amount of O2 and CO2. These quo-
tients refl ect the appropriateness and effi ciency of ventilation at any given metabolic rate. 
Ventilatory equivalents for O2 and CO2 at Wstd (VE/Vo2std and VE/Vco2std) were determined.
Breathing reserve is the “unused” fraction of ventilatory reserve at peak exercise and 
equals the difference (or gap) between maximal voluntary ventilation and VEmax. Breathing 
reserve (%) was calculated by the formula in Table 11 and the directly measured 15-sec-
ond maximal voluntary ventilation (Section 4.2.1.).
Respiratory exchange ratio (RER, Table 11) is an indicator of the status of tissue me-
tabolism (aerobic: RER<1, anaerobic: RER>1) at steady state. RER values can therefore 
serve as rough indices of exercise maximality.
4.2.5. Respiratory muscle strength – maximal airway pressures
In the third study, respiratory muscle strength was assessed during day 2 of the study 
visits by measurement of maximal static airway pressures (Table 10). While seated, the 
patients performed three sets of maximal static inspiratory and expiratory efforts through 
a narrow resistive mouthpiece connected to a pressure sensor. Means (three acceptable 
efforts) for maximal static inspiratory (PImax) and expiratory (PEmax) airway pressures were 
determined from graphic time-pressure plots.
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4.2.6. Biochemical determinations
On each study visit (fi rst and third studies), an indwelling catheter was inserted into the 
antecubital vein for the whole duration of the visit in order to perform repeated blood 
sampling for biochemical assays. In the second study, a single venous puncture was done 
for blood sampling.
Plasma catecholamines
During the study visits (fi rst study), venous blood was sampled for determination of plasma 
concentrations of NA and DA, and of MHPG, a COMT-dependent metabolite of NA. These 
samples were drawn before (0-value) and 2 hours after study-drug intake (Table 10).
Before the exercise tests (third study) and after a 30-minute rest in a supine position 
in a sound-controlled room, a 10-ml volume of venous blood was drawn through an ind-
welling catheter into a vacuum tube for a baseline plasma NA assay (Table 10). The other 
sample was drawn at peak, or immediately after peak exercise.
In both studies, the blood samples were drawn into tubes containing an Na2EDTA an-
ticoagulant (Venoject). The sample tubes were kept in an ice bath and centrifuged (3000 
rpm for 10 minutes) at +4 °C within 15 minutes of sampling. The separated plasma was 
pipetted into two plastic tubes which were immediately deep-frozen to -20 °C and stored 
at -80 °C until delivery for analysis.
All the assays were performed at the Department of Pharmacology, University of 
Turku. The assays for NA and DA were performed by use of high-pressure liquid chro-
matography (HPLC) with coulometric electrochemical detection (Coulochem 5100A, ESA 
inc., Bedford, MA, USA) (295, 296). With the same HPLC apparatus, the MHPG assay was 
performed according to the method described by Scheinin and co-workers (295) with a 
slight modifi cation of the method of sample purifi cation and concentration by applying 
solid-phase extraction with Bond-Elut PH minicolumns (Analytichem International, Harbor 
City, CA., USA).
The variables assessed were the concentrations of plasma NA, DA, and MHPG at base-
line and at 2 hours (fi rst study), and the concentration of plasma NA at rest (CNArest) and at 
peak exercise (CNApeak), and change in plasma NA (∆CNA) (third study).
COMT and MAO-B activities
In the fi rst study, venous blood for the determination of S-COMT activity in erythrocytes 
was sampled on the second and third study visits, fi rst before drug intake (baseline, 0-
value) and then one hour after drug intake (Table 10). Each sample consisted of 10 ml of 
blood collected into an EDTA-tube, which was kept in an ice bath until centrifugation. 
After centrifugation (1500 g at +4 °C) for 10 minutes, the plasma and the upmost (plate-
let-rich) cell layer were separated and discarded. The remaining fraction of red blood cells 
was washed three times by mixing it with ice-cold 0.9% sodium chloride solution of two 
times the sample volume and centrifuging it at 1500 g and at  +4 °C for 10 minutes. The 
samples were then deep-frozen to the storage temperature of -80 °C until analysis.
Determination of S-COMT activity was done at the Department of Pharmacology, Uni-
versity of Helsinki. Before the assay, the erythrocytes were hemolyzed osmotically on ice 
after mixing them with cold 1 mM sodium phosphate buffer (pH 7.4) of three times the 
sample volume. The supernatant was then separated by centrifugation at 20 000 g and at 
+4 °C for 20 minutes. The assay was performed by HPLC with electrochemical detection 
using 3,4-dihydroxybenzoic acid as a substrate (297).
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Two hours after study drug intake on each study visit, a 10-ml sample of venous 
blood was drawn into a chilled EDTA tube for determination of platelet MAO-B activ-
ity. These tubes were kept in an ice bath and centrifuged at 900 rpm (110 g) and at
+5 °C for 30 minutes (Plasma R1000, Jouan, Saint Herblain, France) within one hour 
of sampling. The platelet-rich fraction (supernatant) was then manually separated with
a pipette and transferred to plastic tubes containing 0.1 ml of 100 mM EDTA. These
tubes were shaken, and the platelets were precipitated by centrifugation at 3000 rpm 
(1300 g) and at +5 °C for 15 minutes. After discarding of the supernatant, the platelets in 
the remaining pellet were dispersed by addition of two ml of cold 0.1 M phosphate buffer 
(pH 7.4). After re-centrifugation at 2500 rpm (900 g) and at +5 °C for 10 minutes, the 
supernatant was again discarded, and the walls of the test tubes were dried with cotton 
swabs. A volume of 0.5 ml of cold 0.1 M phosphate buffer (pH 7.4) was added without 
mixing into the samples tubes, which were then capped, deep-frozen, and stored at
-80 °C until analysis.
The MAO-B activity in the samples was determined radiochemically (1214 Rackbeta, 
LKB, Wallac, Turku, Finland), with 14C-phenylethylamine as a substrate, at the Bioanalyti-
cal laboratory of Orion Pharma, Turku (298, 299). The intra- and inter-assay coeffi cients 
of variation (CV) of the method were 4.4% and 11.0%.
Pharmacokinetics of L-dopa and its metabolites
During each study visit of the fi rst study, repeated sampling of blood (Table 10) from the 
antecubital vein was performed to determine plasma concentration of L-dopa and its 
metabolites. Each sample consisted of 10 ml blood collected into a chilled vacuum EDTA 
tube. These tubes were kept in an ice bath and centrifuged at +4 °C. After centrifuga-
tion, 500 µl of plasma was pipetted into each of the two Eppendorf tubes containing
25 µl of 10% sodium metabisulfi te. After mixing, the tubes were deep-frozen to -20 °C 
and stored at -80 °C until analysis.
For each time-point of sampling, the plasma concentrations of L-dopa, 3-OMD, 
DOPAC, and HVA were determined by HPLC with electrochemical detection (300) at the 
Chemical Research Department of Orion Pharma. The quantization range of the method 
was 20 to 8000 ng/ml for L-dopa, 200 to 16000 ng/ml for 3-OMD, and 20 to 2000 ng/ml 
for both DOPAC and HVA. The detection limit of the assay at a signal-to-noise ratio of
3 was 7 pg for L-dopa and DOPAC, 10 pg for 3-OMD, and 6 pg for HVA. The limit of
determination was set to 20 ng/ml for all four analytes. The intra-assay CVs for all ana-
lytes, i.e., the precision of the method, was <7% at a concentration of 20 ng/ml and <4% 
at a concentration of 200 and 2000 ng/ml. The inter-assay CV for all analytes was <9% 
at 80 ng/ml and <6% at 800 ng/ml. The Cmax and Tmax of L-dopa were determined directly 
from the plasma concentration-time data, whereas its t1/2 was calculated. The areas under 
the plasma concentration-time curves for L-dopa, 3-OMD, DOPAC, and HVA from base-
line to 6 hours (AUC0–6h) were calculated by the linear trapezoidal rule (301).
Pharmacokinetics of entacapone and its Z-isomer
The schedule of blood sampling for determination of entacapone and its Z-isomer from 
plasma was identical to that of L-dopa and its metabolites (Table 10). The samples were 
fi rst drawn into vacuum EDTA tubes, then immediately centrifuged at +4 °C, after which 
1.5 ml aliquots of plasma were separated and pipetted into glass tubes, deep-frozen to 
-20 °C, and delivered for analysis at the Chemical Research Department of Orion Pharma. 
At all stages of the handling and storing process, the samples were shielded against sun-
light with thin aluminum foil.
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The plasma concentrations of entacapone and its Z-isomer were determined from the 
samples by similar analytical methods as those for L-dopa and its metabolites (302). The 
pharmacokinetic parameters (Cmax, Tmax, t1/2 and AUC0-6h) of entacapone and its Z-isomer 
were calculated accordingly. The quantization range of the method was 10 to 4000 ng/ml 
for entacapone and 10 to 500 ng/ml for its Z-isomer. The detection limit of the assay at 
the signal-to-noise ratio of 3 was 150 pg. The limit of determination was 10 ng/ml for 
both isomers. The intra-assay CV for both isomers was <10% and ~5% at 10 and 200 
ng/ml. For entacapone, the CV was 3% at 4000 ng/ml. The inter-assay CV for entaca-
pone was 15%, <7%, and <3% at 20, 200, and 2000 ng/ml. The inter-assay CV for the 
Z-isomer was 15% and <3% at 20 and 200 ng/ml.
3-O-methyldopa
Because substantial reduction in 3-OMD formation is observable only after long-term 
(days or more) treatment with COMT inhibitors (14), plasma 3-OMD can serve as an
indicator of treatment effect and compliance. During the last two study visits of the 
third study, a 5-ml venous blood sample was drawn into an EDTA tube concomitantly 
with the baseline NA sample. This tube was kept in an ice bath and then centrifuged at
+4 °C for 10 minutes no later than 30 minutes after sampling. From the separated plas-
ma, two aliquots of 1.0 ml each were pipetted into Eppendorf tubes containing 25 µl of 
20% sodium metabisulfi te. The tubes were capped, mixed, deep-frozen to -20 °C, and 
fi nally stored at -70 °C until analysis.
The determination of plasma 3-OMD concentration was carried out at the Chemical 
Research Department of Orion Pharma, Espoo, by reversed-phase HPLC with ampero-
metric detection (300). The limit of quantization of the method was set at 0.10 µg/ml 
of 3-OMD. The intra-assay CVs at 3-OMD concentrations of 0.10, 0.61, 4.10, and 12.30 
µg/ml were 5.8, 2.8, 1.3, and 0.5%.
Blood and urine safety assessments
In addition to assessment of biochemical safety parameters at screening, blood was sam-
pled into EDTA tubes for safety assays after each treatment period, at the end of each 
washout, and post-study. Assessments included blood count (hemoglobin, leukocytes, 
erythrocytes, erythrocyte volume proportion, and thrombocytes), serum glucose, sodium, 
potassium, creatinine, alanine transaminase, aspartate transaminase, gamma glutamyl 
transferase, alkaline phosphatase, and uric acid. A urine sample was collected for deter-
mination of urinary protein and glucose. The biochemical safety parameters were deter-
mined according to routine methods at Medix Clinical Laboratories, Kauniainen, Finland. 
The clinical signifi cance of values outside the corresponding reference range (provided by 
Medix) was evaluated case-by-case.
4.2.7. Assessment of motor response to L-dopa
In the fi rst two studies, clinical response to treatment was assessed with clinical rating 
scales. Evaluation of the duration and magnitude of motor response to a drug dose by 
use of repeated assessments of clinical rating scales constitutes the L-dopa test. Clinical 
responses were rated in relation to motor disability and dyskinesias. The same observer 
(J.L.) conducted the scorings throughout the studies.
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Unifi ed Parkinson’s Disease Rating Scale (UPDRS), Part III
Part III of the UPDRS (Version 3.0) (79), modifi ed slightly by including the grading of arm 
swings (0 = normal, 1 = possibly diminished, 2 = slightly diminished, 3 = markedly dimin-
ished, 4 = absent) (234) to the scale, was used in the assessment of motor response. Each 
item was scored on a 5-point scale with the total score ranging from zero (normal motor 
state) to 104 (maximal motor disability). Before drug intake on the mornings of study vis-
its, the scoring was performed either once (second study) or twice at 30-minute intervals 
(fi rst study, Table 10). This fi rst score (the mean of the two in the fi rst study) constituted 
the baseline score. After study drug intake, scoring was done at 30-minute intervals over 
the next 6 hours in both studies. A reduction of >10% in UPDRS motor score from the 
baseline score was defi ned as indicating the onset of clinical response (= ”starting time”). 
Likewise, the end of clinical response was considered when the score had returned within 
<10% of the baseline score (= “end time”). The calculated interval between these two 
time-points of assessment was defi ned as the duration of clinical response  (= ON-time). 
The magnitude of clinical response, i.e., the difference between the lowest score of the 
day and the baseline score, was calculated. The mean daily motor score, defi ned as the 
mean of the consecutive scores (n=13) over a visit, was calculated (fi rst and second stud-
ies). In the second study, the total daily motor score, defi ned as the sum of all consecutive 
scores (n=13) over visit was also determined.
In the third study, the modifi ed UPDRS motor score was assessed twice during study 
visits (Table 10), fi rst before and then after exercise. The difference between these two 
scores was calculated.
Abnormal Involuntary Movement Scale
In the second study, the assessment of clinical response included repeated rating of dys-
kinesia according to the Abnormal Involuntary Movement Scale (AIMS) (303, 304). AIMS 
constitutes a rating of dyskinesias in seven different body regions by a 5-point scheme (0 
= absent, 1 = possibly present, 2 = mild, 3 = moderate, 4 = severe/disabling). The total 
AIMS score ranges from 0 (no dyskinesias) to 28 (maximal dyskinesia). The AIMS score 
was rated in conjunction with assessment of the modifi ed UPDRS motor score (Table 10). 
The sum of all consecutive scores over a visit was defi ned as the total daily AIMS score. 
The highest (peak) score of the day was considered to represent the magnitude of dys-
kinesias.
4.2.8. Assessment of sleep
In the fi rst two studies, the study visits were preceded by a quantitative assessment of 
sleep maintenance using 24-hour monitoring of ambulatory motor activity by an accel-
erometric technique (actigraphy). For that purpose, the patients arrived at the Outpatient 
Department on each previous morning for the mounting of a wrist-worn activity-moni-
toring device. The activity monitor (Motionlogger Actigraph® MINI wrist unit, Rev. 1.2, 
Ambulatory Monitoring, Inc., Ardsley, NY, USA) contained a piezo-electric accelerometer 
(Vernitron bimorph transducer beam), which quantifi ed mean motor activity over any 
chosen unit of time (epoch) for storage at a sampling rate of 10 Hz. A Zero Crossing 
mode (activity count generated with each change in signal voltage in relation to reference 
voltage) of registration was applied. Epoch length was set to 25 seconds. The wrist unit 
was always mounted on the same side for each patient, preferably the side with fewer 
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parkinsonian symptoms. The patients were encouraged to maintain their habitual diur-
nal pattern of activities, and to remove the unit only when taking a bath. The unit was 
detached on each study visit morning upon arrival at the Outpatient Department. The 
device initialization, data retrieval, storage, and analysis were performed with a specifi c 
Actigraph Interphase Unit connected to a PC equipped with Action® software (Ver. 1.23, 
Ambulatory Monitoring Inc.). Sleep actigraphy was supplemented by a patient-rated sleep 
questionnaire, in which times for “lights-out,” awakening, and naps were recorded. From 
sleep actigraphy and questionnaire data, duration of sleep (from “lights-out” to awaken-
ing) and mean motor activity during sleep could be calculated.
4.2.9. Adverse events (AE)
During each study visit, AEs were actively inquired about before drug intake, before dis-
charge (fi rst and second studies), and also before and after each exercise test (third study). 
They were also inquired about at each safety visit and post-study. AEs were characterized 
by type, time of onset (and resolution if applicable), temporal course, severity and, if pos-
sible, assumed causality regarding ongoing treatment.
The frequency (times reported/observed) of each type of AE, and the number of pa-
tients with ≥1 AE per treatment were determined.
4.3. Data management and statistical methods
4.3.1. Data management
The original data were fi rst fed manually into a relational database (Rdb) and then down-
loaded to Statistical Analysis System (SAS) software in a VAX/VMS environment. The data 
were listed from the SAS database and crosschecked for errors in data entry by compari-
son of the lists with the original data before performance of any statistical analyses.
After making corrections to the database, the data were transferred for statistical 
analysis to either (fi rst and second studies) Consultant Group Covariance Ltd., Helsinki, 
Finland, using SAS Ver. 6.08 statistical package (SAS Institute Inc., Cary, NC, USA) in a
Microsoft Windows environment on a PC, or (third study) Clinical Research Services, 
Turku, where the analyses were performed with SAS Ver. 6.10.
4.3.2. Statistical methods
First study
Statistical methods were applied in testing for differences in outcome variables between 
the two study treatments (Table 9), and between each study treatment and control
(L-dopa/DDC inhibitor only). The signifi cance level was set at 0.05. Descriptive statistics 
(mean, standard deviation, median, minimum, and maximum values) and estimates of 
95% confi dence intervals (CI95) for means were calculated for all discrete and continuous 
data.
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For parametric outcome variables, the analyses were carried out with mixed-model 
analysis of variance (ANOVA) for crossover design. The normality of distribution was ex-
amined graphically using a box-and-whiskers plot and normal probability plot. The good-
ness-of-fi t of covariance matrix was tested by the asymptotic likelihood ratio test. The 
analyses were performed with the MIXED procedure using type III sums of squares as the 
basis of inference. Orthogonal contrasts were used in testing for differences between 
control and the study treatments. Whenever parametric ANOVA was not applicable, e.g., 
in cases of discrete data or non-normal distribution, a non-parametric signed rank test 
was applied by use of the NPAR1WAY procedure of SAS. Differences between treatments 
were then tested with the Kruskal-Wallis test.
Differences between means of hemodynamic (BP, HR) and clinical response variables 
(mean daily motor score, starting time, ON-time, magnitude of motor response derived 
from the modifi ed UPDRS part III) were analyzed with mixed-model ANOVA for repeated 
measures, with the study visit as the repeated factor. ANOVA was used for testing differ-
ences in pharmacokinetic outcome variables (except for Tmax) for L-dopa, its metabolites 
(3-OMD, DOPAC, and HVA), and entacapone and its Z-isomer, in differences in plasma 
catecholamine levels (DA, NA, MHPG) and in erythrocyte S-COMT and platelet MAO-B 
activities. L-dopa Tmax was tested with the Kruskal-Wallis test, as were differences in du-
ration and mean motor activity during sleep. Descriptive statistics and estimates for CI95 
of means were calculated for biochemical safety parameters. AEs were characterized by 
their frequency of occurrence.
Second study
Differences in outcome variables were tested between the three study treatments
(Table 9) and between each study treatment and control (L-dopa/DDC inhibitor only). The 
two-sided signifi cance level (p-value) was set at 0.05. Descriptive statistics were calcu-
lated and CI95 of means estimated for all discrete and continuous data.
In most cases, a parametric Gaussian mixed-model of ANOVA for a crossover design 
(305, 306) was applied in the statistical testing for differences between treatments, as 
well as in testing for period and carry-over effects.
Differences in hemodynamic variables (BP, HR) and in diurnal HRmean (Holter) were 
tested with the Gaussian mixed-model of ANOVA. Differences in clinical motor (modifi ed 
motor UPDRS: total daily motor score, starting time, ON-time, magnitude of response) 
and dyskinesia (total daily AIMS score, peak AIMS score) response variables were tested 
with ANOVA for repeated measures, followed by the Newman-Keuls test. In the analysis 
of motor disability, the modifi ed UPDRS motor score at screening served as a covari-
ate. Differences in the duration and mean motor activity during sleep were tested with 
the Kruskal-Wallis test, and differences in the occurrence of arrhythmias (SVES and VES) 
during ambulatory ECG by the non-parametric Friedman test. Descriptive statistics and 
estimates for CI95 of means were calculated for biochemical safety parameters. AEs were 
characterized by their frequency of occurrence, and the differences in number of patients 
with AEs were tested with McNemar’s test.
Third study
When differences in outcome variables between the two study treatments (Table 9), and 
between each study treatment and control (overnight drug withdrawal) were tested, a p-
value <0.05 was considered signifi cant. Outcome variables with normal distribution were 
summarized by mean, standard deviation, minimum, and maximum, whereas median, 
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minimum, fi rst quartile, third quartile, and maximum were used in describing variables 
with non-normal (skewed) distribution.
Baseline comparisons of variables between the two study treatments were carried 
out with one-way ANOVA (normal distribution) or the Wilcoxon rank sum test (non-
normal distribution).  For outcome variables with normal distribution, treatment com-
parisons were accomplished with a model of ANOVA for repeated measures appropriate 
for the underlying crossover design, incorporating fi xed effects for sequence, period, 
and sequence-by-period interaction. Both the carry-over and the treatment effects were 
estimated (including CI95) and tested by use of contrasts within this basic model. The 
statistical comparison between study treatments and control were carried out with the 
Wilcoxon signed rank test. In case of non-normally distributed variables, the Wilcoxon 
rank sum test served to detect possible carry-over or period effects.
The comparison of cardiovascular autonomic and cardiorespiratory exercise respons-
es, airway pressures, motor disability, diurnal HRmean, plasma NA, and 3-OMD between 
study treatments and between study treatments and control were performed with ei-
ther repeated-measures ANOVA appropriate for cross-over design (normally distributed 
variables) or the Wilcoxon rank sum and signed rank tests (non-normally distributed vari-
ables). In statistical analysis of spiroergometric data, the between-treatment comparisons 
of each variable were performed between values measured at Wmax/3’ and at Wstd. Dif-
ferences in the occurrence of arrhythmias (SVES and VES) during ambulatory ECG were 
tested with the Wilcoxon signed rank test.  Descriptive statistics and estimates for CI95 
of means were calculated for biochemical safety parameters. AEs were tabulated, and 
number of patients with AEs was compared between treatments with McNemar’s test.
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5. RESULTS
5.1. Cardiac rhythm and hemodynamics
5.1.1. Responses during L-dopa test (I, II)
Selegiline had no signifi cant effect on mean daily systolic BP, diastolic BP, or HR in 13
L-dopa-treated PD patients on entacapone after repeated dosing of the drugs for 2 weeks 
(I). In comparison to control, the mean daily values for systolic and diastolic BP (both
supine and standing) were reduced (p < 0.01–0.001) after 2 weeks of entacapone
therapy, either with or without selegiline, whereas mean daily HR remained unchanged 
(Table 3 in publication I, as “Table 3/I”).
No statistically signifi cant differences appeared in mean daily systolic BP, diastolic BP, 
or HR (Table 12), or in their mean daily changes (systolic BP and HR) during the orthostatic 
test (Table 1/II) between selegiline, entacapone, or entacapone + selegiline after 2-week 
administration of these treatments as adjuncts to L-dopa in 16 PD patients (II).
No clinically signifi cant ECG changes were observable (I, II). The abnormal fi ndings 
(one of each) already present at screening, i.e., fi rst degree atrioventricular block (I), left 
anterior fascicular block (I), right bundle-branch block (II), and left ventricular hypertrophy 
(II), remained unchanged throughout the studies.
Table 12. Daily values (mean ± SD) for systolic blood pressure (BP), diastolic BP, and heart 
rate (HR) during orthostatic testing (II) of Parkinson’s disease patients.
Daily BP and HR
Treatment
LD (control) LD + E LD + S LD + E + S
Systolic BP, supine (mmHg) 142 ± 13 134 ± 12 133 ± 8 136 ± 11
Systolic BP, standing (mmHg) 128 ± 19 120 ± 17 118 ± 16 120 ± 12
Diastolic BP, supine (mmHg) 182 ± 8 177 ± 7 177 ± 5 178 ± 7
Diastolic BP, standing (mmHg) 177 ± 13 172 ± 11 172 ± 10 172 ± 11
HR, supine (beats/min) 168 ± 9 164 ± 9 165 ± 10 164 ± 10
HR, standing (beats/min) 176 ± 11 172 ± 9 175 ± 8 174 ± 9
Assessments were done fi rst before (control), and then after 2 weeks on each study treatment. 
LD, L-dopa; E, entacapone; S, selegiline. N=14 for each group. Differences between study 
treatments not statistically signifi cant.
5.1.2. Responses to maximal exercise (IV)
For 15 PD patients, peak exercise values for systolic BP, diastolic BP, or HR were not signifi -
cantly changed after one-week treatment with entacapone when compared to one-week 
treatment with placebo, both given as adjuncts to L-dopa (Figs. 6a-c). Lower values for di-
astolic BP at peak exercise (p < 0.05) were measured after entacapone with L-dopa when 
compared to those measured during the control (run-in) test after overnight withdrawal 
of L-dopa (Fig. 6b). The differences in either systolic BP or HR at peak exercise were not 
statistically signifi cant between control and study treatments (Figs. 6a and 6c).
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Figs. 6a-f. Group means (heavy horizontal bars) and individual values (symbols) for systo-
lic blood pressure (BP), diastolic BP and heart rate (HR) measured both at peak (Figs. 6a-c)
and at submaximal (Figs. 6d-f) exercise level (IV), fi rst after overnight withdrawal of L-dopa (Con-
trol,{), and then after one week on either entacapone 200 mg t.i.d./q.i.d. (LD+E, ∆) or placebo 
(LD, ) as adjuncts to each dose of L-dopa. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
a. b.
c. d.
e. f.
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Entacapone, when compared to placebo, showed no signifi cant effect on systolic BP, 
diastolic BP, or HR at a submaximal exercise level (Figs. 6d-f). Systolic and diastolic BPs 
at submaximal exercise level were lower (p < 0.01 - 0.001) after L-dopa, both with and 
without entacapone (Figs. 6d and 6e, respectively). HR at submaximal exercise level was 
lower (p < 0.05) after placebo + L-dopa, whereas the difference between control and 
entacapone + L-dopa was not statistically signifi cant (Fig. 6f).
Co-administration of entacapone with L-dopa was not associated with clinically signif-
icant changes in exercise ECG. None of the fi ndings observed during the tests were symp-
tomatic or required intervention (e.g., medication, premature termination of exercise, 
extended follow-up). No clinically signifi cant cardiac conduction abnormalities or arrhyth-
mias occurred. Two patients had monofocal ventricular ectopic beats at peak exercise: 
one after entacapone + L-dopa, and the other both during control and after placebo + 
L-dopa. Each of the exercise tests in one study patient (62-year-old male) was associated 
with asymptomatic, low-amplitude, work-rate-dependent horizontal ST-segment depres-
sion. He had neither a history of ischemic heart disease nor pre-disposing risk factors for 
cardiovascular disease; the fi ndings, consistent with myocardial ischemia, demonstrated 
rapid normalization during post-exercise follow-up.
5.1.3. Ambulatory ECG (II, IV)
Administration of entacapone, selegiline, or both together as adjuncts to L-dopa for 2 
weeks (II) did not signifi cantly change the mean ambulatory HR of 14 patients with PD 
(Fig. 7a). No signifi cant differences in the occurrence of supraventricular (Fig. 7b) or ven-
tricular (Fig. 7c) extrasystoles emerged, either between the study treatments or between 
study treatments and control. Occurrence of non-sustained ventricular tachycardia (Table 
2/II) was not increased with entacapone therapy, either with or without selegiline.
When compared to placebo + L-dopa, one-week administration of entacapone with 
each dose of L-dopa (IV, unpublished results) changed neither mean HR (Fig. 7d) nor the 
occurrence of supraventricular (Fig. 7e) nor ventricular (Fig. 7f) extrasystoles.
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a.
b.
c.
d.
e.
f.
Figs. 7a-f. Group means (bars in Figs. 7a,d), medians (Figs. 7b-c,e-f), and individual values 
(symbols) for mean diurnal heart rate (HR) and the number of supraventricular (SVES) and ven-
tricular (VES) extrasystoles during a 24-hour ambulatory ECG registration. Second study (Figs. 
7a-c): fi rst during L-dopa (Control,), and then after 2 weeks of either selegiline 10 mg o.d. 
(LD+S, ◊), entacapone 200 mg t.i.d/q.i.d. (LD+E, ∆), or entacapone plus selegiline (LD+E+S, z) 
as adjuncts to L-dopa. Third study (Figs. 7d-f): after one week of either entacapone 200 mg 
(LD+E, ∆) or placebo (LD, ), both given t.i.d./q.i.d. as adjuncts to each dose of L-dopa. No 
signifi cant differences between groups. Log scale Y-axis in Figs 7b-c,e-f.
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5.2. Effects on cardiovascular autonomics (III)
5.2.1. Responses to deep breathing
Mean HR variation during deep voluntary breathing was not signifi cantly altered by one-
week therapy with entacapone as an adjunct to each dose of L-dopa when compared to 
the corresponding placebo regimen (Table 13). Differences between study treatments and 
control were also non-signifi cant.
Based on the categorization of individual HR responses to deep breathing by Piha 
(287), the number of non-normal (borderline/pathologic) responses was similar between 
control (2/1), placebo plus L-dopa (2/1), and entacapone plus L-dopa (2/0). The remaining 
majority of HR responses were considered normal.
Table 13. Parameters (mean ± SD) of cardiovascular autonomic function (III).
Function tests of the cardiovascular 
autonomic nervous system
Treatment
Control LD + P LD + E
Deep breathing test
• Deep breathing difference 
• (beats/min)
111.9 ± 6.5 112.3 ± 8.3 112.7 ± 7.0
Orthostatic test
• HRmax/HRmin 11.18 ± 0.06 21.18 ± 0.15 11.16 ± 0.16
• ∆SBP3-0min (mmHg) 1-5.5 ± 12.0 1-8.5 ± 17.1 -14.5 ± 28.3
• ∆DBP3-0min (mmHg) 1.5.0 ± 6.2 123.4 ± 7.8 113.7 ± 11.2
• ∆HR3-0min (beats/min) 114.5 ± 8.3 115.5 ± 9.2 115.1 ± 11.4
• ∆HR1-0min (beats/min) 113.6 ± 6.9 115.9 ± 8.0* 116.2 ± 10.8
Valsalva test
• Valsalva ratio 11.34 ± 0.24 11.34 ± 0.30 11.39 ± 0.30
Isometric hand grip test
• ∆DBP (mmHg) 115.5 ± 9.6 114.9 ± 8.9 113.0 ± 8.1
Assessments were done fi rst after overnight withdrawal of L-dopa (control), and then after 
one week on L-dopa with either entacapone 200 mg or placebo. LD, L-dopa; P, placebo; E, 
entacapone; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; HRmax/
HRmin, maximum orthostatic R-R interval variation; ∆, change (over time period).
1N=13, 2N=14, otherwise N=15. Control vs. placebo plus L-dopa: *, p < 0.05.
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5.2.2. Responses to orthostatic challenge
Entacapone had no effect on the maximum orthostatic R-R interval (or HR) variation 
when compared to placebo, when both were given as adjuncts to L-dopa for one week 
(Table 13). In comparison to maximum HR variation measured during the control test, L-
dopa did not affect this ratio either with or without entacapone.
The number of borderline abnormal/pathologic responses in maximum HR variation 
during the orthostatic test (287) was 2/0 during control, 5/1 after entacapone plus L-dopa, 
and 4/1 after placebo plus L-dopa. All the other responses were classifi ed as normal.
Differences in the BP and HR parameters were not statistically signifi cant between 
entacapone and placebo, or between study treatments and control, with the exception 
of the HR change during one minute being higher (p < 0.05) after placebo plus L-dopa 
than during control treatment (Table 13).
One patient had systolic orthostatic hypotension during the control test, whereas this 
was observed in three patients after administration of entacapone and four after placebo, 
in conjunction with L-dopa (Table 2/III). Diastolic orthostatic hypotension was apparent in 
two patients after entacapone plus L-dopa and in one after placebo plus L-dopa, but not 
during the control test.
L-dopa-related symptomatic orthostatic hypotension, either systolic or diastolic, ap-
peared in two patients, neither of which had orthostatic hypotension during the control 
test. One of these developed symptomatic orthostatism with dizziness after both entaca-
pone (55 and 10 mmHg reductions in systolic and diastolic BP) and placebo (42 and 13 
mmHg reductions). The other patient had symptomatic orthostatism (26 mmHg systolic 
BP decrease) after L-dopa with placebo, but not after L-dopa with entacapone.
One patient demonstrated systolic orthostatic hypotension after entacapone plus L-
dopa that was not observable after administration of placebo plus L-dopa. This event was 
asymptomatic. In another patient, a consistent and marked systolic orthostatism occurred 
during each test, including control (–40 mmHg), after entacapone plus L-dopa (–100 
mmHg), and after placebo plus L-dopa (–42 mmHg). She was, however, symptomatic 
only during the control test.
Normal hemodynamic reactions after 3 minutes of standing were observable in 13 
patients during control, in 11 patients after L-dopa with entacapone, and in 10 patients 
after L-dopa with placebo. A hypoadrenergic reaction occurred in one patient during 
control and in three and four patients after L-dopa with either entacapone or placebo, 
respectively. A hyperadrenergic reaction was consistently evident in one patient, both 
during control and after each study treatment.
5.2.3. Responses to the Valsalva maneuver
No signifi cant differences in the Valsalva ratio determined after L-dopa intake were ob-
servable between entacapone and placebo, when these were administered with each 
dose of L-dopa for one week. Neither were there signifi cant differences between control 
and the study treatments (Table 13).
In comparing these results with reference values for the Valsalva ratio (287), a bor-
derline abnormal response was evident in fi ve patients during control, in two after en-
tacapone plus L-dopa, and in fi ve after placebo plus L-dopa. One pathologic response 
occurred after each study treatment; other responses were considered normal.
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5.2.4. Responses to sustained isometric effort
No differences appeared in diastolic BP change during 3 minutes of sustained isometric 
effort between entacapone and placebo, after administration of each in conjunction with 
L-dopa for a one-week period, nor between the control and either of these study treat-
ments (Table 13).
Comparison of results of diastolic BP change with reference values for isometric effort 
(287) showed borderline abnormal responses in fi ve patients during the control, in four 
after entacapone plus L-dopa, and in fi ve after placebo plus L-dopa. A pathologic response 
occurred in two patients after entacapone plus L-dopa, and in another two after placebo 
plus L-dopa. Other values fell within the range for the predicted normal response.
5.3. The effects on cardiorespiratory performance (IV)
5.3.1. Gas exchange responses to maximal exercise
The maximum O2 uptake was not changed by adding entacapone to L-dopa treatment 
(Fig. 8b). Maximum O2 uptake was higher (p < 0.05) after placebo plus L-dopa than 
during control. The difference between entacapone plus L-dopa and control was not 
signifi cant.
The differences in either maximal exercise ventilation (Fig. 8c) or breathing reserve 
(Fig. 8d) were not statistically signifi cant between the two study treatments, or between 
both study treatments and control.
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5.3.2. Gas exchange responses to submaximal exercise
Entacapone had no signifi cant effect on the submaximal, work-rate standardized O2 up-
take measured 1.5 to 2 hours from L-dopa intake in this sample of 15 patients with PD, 
nor were there any differences in the submaximal O2 uptake between control and the 
study treatments (Fig. 8e). Lower values (p < 0.05) for submaximal O2 pulse were observ-
able after entacapone plus L-dopa than after placebo plus L-dopa. Differences in submax-
imal O2 pulse were not signifi cant between control and either study treatment (Fig. 8f).
After administration of the study drugs with L-dopa, entacapone did not signifi cantly 
change the ventilatory equivalents for either O2 or CO2 at submaximal exercise level when 
compared to placebo (Figs. 8g and 8h, respectively). Submaximal ventilatory equivalent 
for CO2 was lower than control values (p < 0.05) after placebo plus L-dopa, but not after 
entacapone plus L-dopa.
5.3.3. The effects on work capacity
When compared to placebo, entacapone did not change the maximal workload at 1.5 
to 2 hours from its intake with L-dopa in this sample of PD patients (Fig. 8a). Higher 
values for maximal workload were achieved after L-dopa intake, both with entacapone
(p < 0.05) and with placebo (p < 0.01), than during the control test without L-dopa.
5.3.4. Maximal airway pressures
No signifi cant differences appeared in the means for maximal inspiratory airway pressure 
between entacapone (12.9 ± 3.0 kPa) and placebo (12.7 ± 3.5 kPa), each administered as 
an L-dopa adjunct for one week, or between treatments and control (12.0 ± 2.6 kPa).
The mean for maximal expiratory airway pressure was not signifi cantly changed after 
one-week therapy with entacapone plus L-dopa (20.8 ± 4.5 kPa) when compared to 
placebo plus L-dopa (19.1 ± 4.8 kPa). Neither of these differed signifi cantly from control 
values (19.3 ± 4.6 kPa).
5.4. The effects on plasma catecholamines
5.4.1. Catecholamines and metabolites during L-dopa test (I)
Regardless of the use of selegiline, the 2-week co-administration of entacapone with 
L-dopa in 13 PD patients did not alter the plasma concentration of NA or DA measured 
both before and 2 hours after intake of the study drugs (Table 14). Two hours after ad-
ministration of entacapone with L-dopa – both with and without selegiline – a signifi cant 
decrease (p < 0.01 – 0.001) in the concentration of a COMT-dependent NA metabolite, 
MHPG, was, however, observable (Table 14).
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5.4.2. Plasma NA response to exercise (IV)
One-week therapy with entacapone as an adjunct to L-dopa had no signifi cant effect 
on either recumbent or peak exercise levels of plasma NA in 15 PD patients (Table 15), 
nor were there signifi cant differences between values measured during the run-in test 
(without L-dopa) and those measured after L-dopa administration, regardless of the use 
of entacapone. In comparison to recumbent levels of plasma NA, approximately ten-fold 
increases in its concentration occurred at peak exercise, both during control and after 
both study treatments (Table 15).
Table 14. Plasma concentrations (mean ± SD) of noradrenaline (NA), dopamine (DA), and 
3-methoxy-4-hydroxyphenylethylene glycol (MHPG) (I).
Plasma catecholamines Treatment
LD (Control) LD + E LD + E + S
NA (nmol/l)
• 0 h 12.62 ± 1.32 12.02 ± 0.94 11.93 ± 0.96
• 2 h 11.25 ± 0.57 11.01 ± 0.50 11.16 ± 0.67
DA (nmol/l)
• 0 h 11.02 ± 0.82 11.29 ± 0.46 11.95 ± 1.21
• 2 h 13.57 ± 2.44 14.30 ± 3.42 14.96 ± 2.81
MHPG (nmol/l)
• 0 h 17.75 ± 6.25 14.42 ± 4.21 112.75 ± 3.11
• 2 h 16.42 ± 4.89 11.58 ± 3.53** 110.27 ± 2.28***
Assessments were done fi rst with L-dopa (control), and then after 2 weeks on L-dopa + en-
tacapone either with or without selegiline. LD, L-dopa; E, entacapone; S, selegiline. 1N=11,
otherwise N=12. Timing of assessment: before (0h), and 2 hours after (2h) drug intake. Con-
trol vs. study treatments: **, p < 0.01; ***, p < 0.001.
Table 15. Rest and peak exercise levels (mean ± SD) of plasma noradrenaline (NA) during 
a maximal work-conducted exercise test (IV).
Plasma noradrenaline
Treatment
Control LD + P LD + E
NA (nmol/l)
• Rest 11.87 ± 0.83 11.72 ± 0.73 11.79 ± 0.78
• Peak exercise 18.67 ± 12.65 21.33 ± 15.69 21.46 ± 15.65
Assessments were done fi rst after withholding L-dopa overnight (control), and then after one 
week on L-dopa with either entacapone 200 mg or placebo. LD, L-dopa; P, placebo; E, enta-
capone. N=15 for each group. No signifi cant differences between treatments.
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5.5. Pharmacokinetic and dynamic responses
5.5.1. Inhibition of S-COMT and MAO-B activities (I)
Entacapone, one hour from its administration with L-dopa, signifi cantly reduced
(p < 0.001) the activity of S-COMT in red blood cells (Fig. 9). The mean decrease in
activity from control was 38% after entacapone plus placebo and 36% after entacapone 
plus selegiline. Selegiline had no effect on S-COMT activity, either at baseline or after one 
hour from intake.
After administration of selegiline for 2 weeks, practically total (> 99.9%) inhibition of 
platelet MAO-B activity was observable (p < 0.001). Entacapone had no effect on platelet 
MAO-B activity (Fig. 10).
Fig. 9. Group means (bars) and 
individual values (symbols) for 
soluble catechol-O-methyl-
transferase (S-COMT) activity in 
red blood cells (I), determined 
before (baseline) and 60 min-
utes after intake of morning 
doses of entacapone 200 mg 
plus L-dopa, with either sele-
giline 10 mg (LD+E+S) or place-
bo (LD+E). Baseline vs. 60 min.:
p < 0.001. Differences between 
selegiline and placebo not sig-
nifi cant.
Fig. 10. Group means (bars) 
and individual values (symbols) 
for platelet monoamine oxidase 
type B (MAO-B) activity (I) at 2 
hours from study drug intake, 
fi rst after L-dopa (Control,  ), 
and then after 2 weeks of L-
dopa with either selegiline 10 
mg o.d. plus entacapone 200 
mg t.i.d./q.i.d. (LD+E+S, z), or 
placebo o.d. plus entacapone 
200 mg t.i.d./q.i.d. (LD+E, ∆).
***, p < 0.001.
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5.5.2. Pharmacokinetics of L-dopa and its metabolites (I)
The bioavailability of L-dopa was signifi cantly enhanced (p < 0.001) by entacapone 200 
mg, both with and without selegiline (Table 16, Fig. 3a/I). Entacapone had no signifi -
cant effect on either the Cmax or Tmax of L-dopa (Table 16). In comparison to control, the 
plasma t1/2 of L-dopa was slightly higher after administration of entacapone, either with 
or without selegiline, as an adjunct to L-dopa. This increase was, however, signifi cant only 
after entacapone plus selegiline (p < 0.05). Selegiline had no signifi cant effect on L-dopa 
pharmacokinetics in entacapone-treated PD patients.
After 2 weeks of treatment with entacapone, signifi cant decreases (p < 0.001) oc-
curred in the bioavailability of both 3-OMD and HVA, the COMT-dependent metabolites 
of L-dopa and DA (Table 16, Figs. 3b,d/I). Selegiline had no effect on the bioavailability of 
either of these metabolites in entacapone-treated PD patients.
Table 16. Pharmacokinetic parameters (mean ± SD) for L-dopa and its metabolites 3-O-
methyldopa (3-OMD), dihydroxyphenyl acetic acid (DOPAC), and homovanillic acid (HVA) 
(I).
Pharmacokinetics:
L-dopa & metabolites
Treatment
LD (control) LD + E LD + E + S
L-dopa
• AUC0-6h (ng/ml x h) 55982 ± 1413 59106 ± 2653*** 58604 ± 2071***
• t1/2 (h) 55.1.2 ± 0.2 55.1.3 ± 0.2 55.1.4 ± 0.3*
• Tmax (h) 55.1.3 ± 1.0 55.1.5 ± 1.0 55.1.5 ± 1.1
• Cmax (ng/ml) 53201 ± 1472 53424 ± 1196 53118 ± 779
3-OMD
• AUC0-6h (ng/ml x h) 47210 ± 16434 27448 ± 12537*** 23248 ± 9503***
DOPAC
• AUC0-6h (ng/ml x h) 55598 ± 61 55264 ± 88*** ‘†††185 ± 85***
HVA
• AUC0-6h (ng/ml x h) 55537 ± 149 55476 ± 171*** 55406 ± 142***
Assessments were done fi rst after L-dopa (control), and then after 2 weeks on L-dopa plus 
entacapone 200 mg t.i.d./q.i.d. plus selegiline 10 mg/placebo o.d. LD, L-dopa; E, entacapone; 
S, selegiline; AUC0-6h, area under the plasma concentration-time curve over 6 hours from drug 
intake; t1/2, plasma elimination half-life; Tmax, time to peak plasma concentration; Cmax, peak 
plasma concentration. N=12 for each group.
Control vs. study treatments: *, p < 0.05; ***, p < 0.001. Selegiline vs. Placebo: †††,
p < 0.001.
The bioavailability of DOPAC, the MAO-dependent metabolite of DA, was signifi cantly 
increased (p < 0.001) after addition of entacapone, either with or without selegiline, to 
L-dopa therapy. This increase was signifi cantly less pronounced after selegiline (p < 0.001) 
than after placebo (Table 16, Fig. 3c/I).
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5.5.3. Pharmacokinetics of entacapone and its Z-isomer (I)
In 12 L-dopa-treated PD patients, the repeated dosing of the MAO-B inhibitor selegiline 
for 2 weeks had no effect on the main pharmacokinetic parameters of either entacapone 
or the Z-isomer of entacapone (Table 17).
5.5.4. Plasma concentration of 3-OMD (IV)
When administered as L-dopa adjuncts for one-week, the concentration of plasma
3-OMD (mean ± SD), the COMT-dependent metabolite of L-dopa, was signifi cantly lower 
(p < 0.001) after entacapone (1.24 ± 0.55 µg/ml) than after placebo (2.58 ± 1.08 µg/ml).
5.6. Effects on clinical response to L-dopa
5.6.1. Motor response to the L-dopa test (I, II)
According to repeated assessments of UPDRS part III, the mean daily motor score of 13 
PD patients (I) was signifi cantly lower (p < 0.01) after concomitant administration of 
entacapone with selegiline than without selegiline as adjuncts to L-dopa (Table 18, Fig. 
11a). The mean daily motor score was also signifi cantly lower (p < 0.001) after both study 
treatments than after control therapy with L-dopa only. No differences appeared in time 
of onset, duration, or magnitude of motor response between the study treatments or 
between treatments and control (Table 18).
Table 17. Pharmacokinetic parameters (mean ± SD) of entacapone and its Z-isomer (I).
Pharmacokinetics:
entacapone & its Z-isomer 
Treatment
LD + E LD + E + S
Entacapone
• AUC0-last (ng/ml x h) 1517 ± 447 1399 ± 553
• Tmax (h) 1.0.8 ± 0.7 1.1.0 ± 0.8
• Cmax (ng/ml) 1232 ± 503 1079 ± 600
Z-isomer
• AUC0-last (ng/ml x h) 1102 ± 36 1104 ± 51
• Tmax (h) 1.0.8 ± 0.7 1.1.2 ± 1.0
• Cmax (ng/ml) 1176 ± 35 1174 ± 43
Assessments were done after 2 weeks on L-dopa plus entacapone 200 mg t.i.d./q.i.d. plus 
either selegiline 10 mg or placebo o.d. LD, L-dopa; E, entacapone; S, selegiline; AUC0-6h, area 
under the plasma concentration-time curve over 6 hours, Tmax, time to peak plasma concen-
tration; Cmax, peak plasma concentration. N=12 for each group. No signifi cant differences 
between treatments.
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No signifi cant differences in mean daily motor score (Table 19) emerged between entaca-
pone, selegiline, or entacapone plus selegiline in 14 PD patients (II). Differences in mean 
daily motor score between control and each study treatment were also non-signifi cant. 
In comparison to control, the total daily motor score (“AUC” of motor disability) was 
signifi cantly reduced (p < 0.05 for all contrasts) after entacapone (by 10%), selegiline 
(by 12%) and entacapone plus selegiline (by 11%) as add-on therapies to L-dopa (Table 
19, Fig. 11b). Differences in the total daily motor score between study treatments were 
non-signifi cant. Neither time of onset, duration, nor magnitude of motor response was 
signifi cantly changed by any of the study treatments (Table 19). 
Table 18. Parameters (mean ± SD) of clinical response to L-dopa based on the motor part 
of the Unifi ed Parkinson’s Disease Rating Scale (UPDRS) (I).
Clinical response:
motor UPDRS
Treatment
LD (control) LD + E LD + E + S
Mean daily scorea -29.6 ± 11.2 (165) -026.9 ± 10.4*** (168) ††25.4 ± 10.4*** (168)
Magnitude of responseb -10.4 ± 6.1 (12) 0-13.1 ± 5.0 (12) --10.5 ± 4.3 (12)
Starting timec (h) -01.0 ± 0.6 (11) 00-1.1 ± 0.7 (11) 0--1.4 ± 0.8 (12)
ON-timed (h) 0-3.1 ± 1.4 (11) 00-2.9 ± 0.8 (11) --03.0 ± 1.3 (12)
Ratings were done repeatedly at half-hour intervals over 6 hours from drug intake, fi rst after 
L-dopa (control), and then after 2 weeks on L-dopa plus entacapone 200 mg t.i.d./q.i.d. plus 
selegiline 10 mg/placebo o.d. LD, L-dopa; E, entacapone; S, selegiline. aArithmetic mean of 
the 13 motor scores over study visit; blowest (best) motor score of the day minus the baseline 
score; conset of clinical response, i.e., time from drug intake when a reduction (improvement) 
in motor score of >10% from baseline score was observed; dduration of clinical response = 
end time (time from drug intake when the difference between motor score and the baseline 
score ≤10% of the baseline score) – starting time. Figures in parentheses indicate number of 
assessments in each group.
Control vs. study treatments: ***, p < 0.001. Selegiline vs. Placebo: ††, p < 0.01.
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Figs. 11a-b. Modifi ed motor (part III) subscores (mean ± SEM) of the Unifi ed Parkinson’s Dis-
ease Rating Scale (UPDRS), assessed fi rst before (0 h), and then repeatedly after intake of drugs 
(arrow) in Studies 1 (Fig. 11a, n=10-12) and 2 (Fig. 11b, n=13-14). The fi rst assessment was 
done after intake of L-dopa (Control), and then after 2 weeks of L-dopa with entacapone 200 
mg t.i.d./q.i.d. (LD+E), entacapone 200 mg t.i.d./q.i.d. plus selegiline 10 mg o.d. (LD+E+S), or 
selegiline 10 mg o.d. (LD+S, in Study 2). Higher score indicates greater motor disability. See 
Section 5.6.1. and Tables 18 and 19 for analyses of results.
b.
a.
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5.6.2. Dyskinesias during the L-dopa test (II)
In comparison to control therapy with L-dopa only, the mean increase in total daily AIMS 
score (“AUC” of dyskinesia) was 60% after entacapone, 47% after selegiline, and 95% 
after entacapone plus selegiline as L-dopa adjuncts in 14 PD patients (Table 19, Fig. 12), 
but only the difference between control and entacapone plus selegiline was signifi cant 
(p < 0.01). Differences in total daily AIMS score between any two study treatments were 
non-signifi cant. Differences in peak AIMS score were not signifi cant between study treat-
ments, or between each study treatment and control (Table 19).
Table 19. Parameters (mean ± SD) of clinical response to L-dopa based on the motor part 
of the Unifi ed Parkinson’s Disease Rating Scale (UPDRS) and the Abnormal Involuntary 
Movement Scale (AIMS) (II).
Clinical response:
motor UPDRS & AIMS
Treatment
LD (control) LD + E LD + S LD + E + S
Motor UPDRS
• Mean daily scorea -24.2 ± 10.9 (182) 22.0 ± 11.2 (180) -21.6 ± 11.3 (180) 21.8 ± 10.6 (180)
• Total daily scoreb -.315 ± 112 (182) .283 ± 120* (180) -.277 ± 127* (180) -280 ± 116* (180)
• Magnitudec -11.6 ± 8.3 (14) .-9.6 ± 6.4 (14) -10.1 ± 7.4 (14) --8.4 ± 6.3 (14)
• Starting timed (h) -11.1 ± 0.3 (14) 01.3 ± 0.5 (14) 3-1.4 ± 0.9 (14) 31.1 ± 0.2 (12)
• ON-timee (h) -12.6 ± 0.8 (10) 02.2 ± 1.4 (10) 3-2.0 ± 1.2 (10) 32.3 ± 0.7 (10)
AIMS
• Total daily scoref -18.6 ± 12.6 (11) 13.8 ± 15.9 (11) -12.6 ± 17.7 (11) 16.8 ± 19.5**(11)
• Peak scoreg -12.4 ± 2.7 (11) 03.4 ± 3.6 (11) 3-3.5 ± 3.6 (11) 33.9 ± 3.4 (11)
Ratings were done repeatedly at half-hour intervals over 6 hours from drug intake, fi rst after 
L-dopa (control), and then after 2 weeks on L-dopa plus entacapone 200 mg t.i.d./q.i.d., 
L-dopa plus selegiline 10 mg o.d., or L-dopa plus entacapone plus selegiline. LD, L-dopa; E, 
entacapone; S, selegiline; aarithmetic mean of the 13 motor scores over study visit; bsum of all 
the 13 motor scores over study visit; clowest (best) motor score of the visit minus the baseline 
score; donset of clinical response, i.e., time from drug intake when a reduction (improvement) 
in motor score of >10% from baseline score was observed; eduration of clinical response = end 
time (time from drug intake when the difference between motor score and the baseline score 
≤10% of the baseline score) – starting time; fsum of all the 13 AIMS scores over study visit; 
ghighest AIMS score during the study visit. The fi gures in parentheses indicate the number of 
assessments in each group. Control vs. study treatments: *, p < 0.05; **, p < 0.01.
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5.6.3. Effect of exercise on motor response (IV)
Both pre- and post-exercise UPDRS motor scores (mean ± SD) of 15 PD patients who per-
formed a maximal work-conducted bicycle exercise test were lower after administration 
of L-dopa with either entacapone (13.9 ± 8.6 and 15.9 ± 11.5, respectively) or placebo 
(15.8 ± 6.2 and 16.8 ± 6.2, respectively) than were the scores assessed during a run-in 
visit after overnight drug withdrawal (22.7 ± 12.5 and 24.8 ± 12.5, respectively). Within 
each group a trend emerged toward a slight but non-signifi cant deterioration in motor 
function after exercise.
5.6.4. Sleep (I, II)
Differences in either the duration or quality of sleep (Table 20), based on the analysis of 
sleep actigraphy recordings, were not signifi cant between any two study treatments or 
between study treatments and control (I, II).
Fig. 12. Scores (mean ± SEM) for Abnormal Involuntary Movement Scale (AIMS), assessed fi rst 
before (0 h), and then repeatedly after intake of study drugs (arrow) (II). The fi rst assessment 
was done after intake of L-dopa (Control), and then after 2 weeks of L-dopa with selegiline 10 
mg o.d. (LD+S), entacapone 200 mg t.i.d./q.i.d. (LD+E) or entacapone plus selegiline (LD+E+S). 
Higher score indicates more dyskinesia. N=11 for each group. See Section 5.6.2. and Table 19 
for analyses of results.
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5.7. Adverse events (AE)
Of the most common AEs encountered in the fi rst and second studies, most were tran-
sient and either mild to moderate in severity (Table 21).
In the fi rst study, of 12 patients treated with entacapone plus selegiline as L-dopa 
adjuncts, 9 (75%) reported ≥1 AE, as compared to 9 (69%) of 13 of those receiving en-
tacapone plus placebo. The total number of AEs during these treatments was also com-
parable, with 25 reported events during selegiline and 26 during placebo periods. Three 
patients (25%) experienced nausea during treatment with selegiline, whereas no nausea 
occurred during placebo (Table 21).
Table 20. The duration and quality (mean ± SD) of sleep based on ambulatory activity 
monitoring (sleep actigraphy) (I, II).
Sleep assessment with actigraphy
Treatment
LD (control) LD + E LD + S LD + E + S
Duration of sleep (h)
• Study 1 (N=12-13) 46.3 ± 1.2 46.8 ± 1.7 NA 46.3 ± 1.5
• Study 2 (N=12-14) 46.3 ± 1.2 46.5 ± 1.1 46.2 ± 1.3 46.7 ± 1.4
Activity during sleepa (counts/epoch)
• Study 1 (N=12-13) 41.8 ± 60.0 43.2 ± 46.4 NA 39.9 ± 22.2
• Study 2 (N=12-14) 43.6 ± 39.4 48.1 ± 32.8 44.3 ± 30.0 47.4 ± 32.6
Assessments were done fi rst after L-dopa (control), and then after 2 weeks on L-dopa plus 
entacapone 200 mg t.i.d./q.i.d., L-dopa plus selegiline 10 mg o.d. (study 2 only), and L-dopa 
plus entacapone plus selegiline. LD, L-dopa; E, entacapone; S, selegiline; NA, not applicable. 
amean motor activity from “lights-out” to awakening quantifi ed in epochs of 25 sec. duration, 
based on wrist-worn accelerometric assessment (actigraphy).
No signifi cant differences between treatments.
Table 21. The most frequently reported adverse events in Parkinsonian patients (I, II).
Adverse event
First study Second study
LD+E (n=13) LD+E+S (n=12) LD+E (n=14) LD+S (n=15) LD+E+S (n=16)
Fatigue 4 (31%) 2 (17%) 7 (50%) 6 (40%) 2 (13%)
Dizziness 4 (31%) 3 (25%) 1 (7%) 1 (7%) 4 (25%)
Nausea 0 3 (25%) 1 (7%) 0 3 (19%)
Headache 4 (31%) 2 (17%) 0 1 (7%) 2 (13%)
Orthostatic hypotension 0 0 2 (14%) 5 (33%) 2 (13%)
Abdominal pain 2 (15%) 2 (17%) 0 0 1 (6%)
Diarrhea 0 2 (17%) 1 (7%) 1 (7%) 0
Insomnia 0 1 (9%) 0 2 (13%) 4 (25%)
Loss of appetite 1 (8%) 2 (17%) 0 0 1 (6%)
Dry mouth 1 (8%) 0 0 2 (13%) 2 (13%)
Patients with adverse events 9 (69%) 9 (75%) 8 (57%) 11 (73%) 9 (56%)
Occurrence (n) and frequency (% of patients) of the most common (occurring in ≥2 patients 
during any treatment period) adverse events during the 2-week treatment periods, as well 
as number of patients reporting adverse events. LD, L-dopa; E, entacapone; S, selegiline. Be-
tween-group differences in number of patients reporting adverse events non-signifi cant.
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In the second study, of 14 L-dopa treated patients, 8 (57%) reported ≥1 AE during the 2 
weeks on entacapone, 11 (73%) of 15 during treatment with selegiline, and 9 (56%) of 
those 16 receiving treatment with both entacapone and selegiline. These differences in 
number were non-signifi cant. The total number of AEs reported during study treatments 
was 21 for entacapone, 38 for selegiline, and 33 for entacapone plus selegiline. Loss of 
sleep was reported by two (13%) patients during selegiline therapy without entacapone 
and by four (25%) during selegiline with entacapone. No sleep loss occurred during the 
period with entacapone as the sole adjunct to L-dopa. Fatigue occurred least frequently 
during treatment with entacapone plus selegiline (Table 21), whereas dizziness and nau-
sea were most frequently encountered in this group of patients.
In the third study, more (p < 0.05) patients reported AEs during the week on enta-
capone (n=12) than during the week on placebo (n=6). Two patients had nausea during 
entacapone, none during placebo. The number or type of AEs during exercise did not 
differ signifi cantly between treatments. No severe AEs occurred.
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6. DISCUSSION
This thesis is based on the results of two interaction studies on the combined use of 
entacapone and selegiline as adjuncts to L-dopa (I, II), and on the results of one trial on 
cardiovascular autonomic function (III) and cardiorespiratory exercise safety and capacity 
(IV) after repeated dosing of entacapone in L-dopa-treated patients with PD. All three 
studies had a controlled, double-blind, crossover design in order to control for the pla-
cebo effect and to avoid other sources of bias, either observer- or group-based. Washout 
periods used in two of the studies minimized carry-over effects. In general, the study 
methodology was well standardized. In each study, the patients selected were considered 
to represent “typical” cases of PD, and formed a rather homogeneous group in relation 
to disease severity and antiparkinsonian treatment. The original study protocols were fol-
lowed rigorously with no major deviations.
A diverse array of methods and parameters (biochemical, pharmacological, metabolic, 
physiological, clinical) were applied. As a downside, the protocols were rather compli-
cated and time-consuming, thus limiting sample size and statistical power. Duration of 
treatment was measured in days to weeks, thus limiting any conclusions as to the poten-
tial effects of chronic treatment. In addition, the pharmacodynamic effects of selegiline 
recede slowly, resulting potentially in a considerable carry-over effect.
6.1. Cardiorespiratory aspects
6.1.1. Hemodynamics and cardiac rhythm
Some studies show COMT inhibition to alter hemodynamics despite inducing no change 
in the plasma levels of catecholamines. In healthy humans, entacapone potentiates the 
chronotropic effect of isoprenaline without affecting its plasma concentration (277). In 
patients with MSA, entacapone has induced a marked hypersensitivity to phenylephrine 
compared to its effects in healthy controls, in addition to eliciting a moderate and dose-
dependent increase in systolic BP in MSA patients, despite unchanged plasma levels of 
DA, NA, and adrenaline (280). It can therefore be hypothesized that COMT inhibitors may 
have differential effects on plasma and receptor-level concentrations of catecholamines, 
and that their hemodynamic effects may be altered in subjects with signifi cant cardiovas-
cular autonomic dysfunction. According to a microdialysis study in experimental animals, 
entacapone did not change the myocardial interstitial levels of NA, although signifi cant 
increases and decreases occurred in its respective MAO- (DHPG) and COMT-dependent 
(normetanephrine and MHPG) metabolites (307).
Similar to the use of either entacapone or selegiline as a sole adjunct to L-dopa, the 
simultaneous use of these two drugs as L-dopa adjuncts did not signifi cantly change he-
modynamics such as daily supine/standing BP or HR (I, II). The chronic use of selegiline has 
been reported to diminish sympathetic autonomic responses (166) and to be associated 
with orthostatic hypotension in L-dopa-treated PD patients (308). According to the results 
from the current studies, 2 weeks on selegiline – either with or without entacapone – did 
not enhance the orthostatic fall in BP of L-dopa treated patients. The combination ther-
apy with these two drugs was hemodynamically well tolerated, which is in accordance 
with the results from other double-blind, randomized, placebo-controlled phase II studies 
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(234, 239), and also from phase III studies on entacapone (10, 11, 248, 259), in which 
a signifi cant number of patients were also taking selegiline. The 6-month Nordic study 
with nearly half the patients using selegiline detected no signifi cant differences in supine 
or standing systolic BP or HR between the entacapone and placebo treatment arms (11). 
In the 12-month safety study with over 300 PD patients, mean orthostatic fall in systolic 
BP and overall tendency to orthostatic hypotension did not differ between entacapone 
and placebo, despite the frequent (> 80%) use of selegiline in both groups (259). Similar 
results were obtained in the German-Austrian multicenter study in which use of selegiline 
was less (52–56%) common (248).
Although the cardiac safety of entacapone has been extensively studied in parkinso-
nian patients, for instance with intermittent ECG recordings, a more sensitive method for 
detecting cardiac rhythm disturbances, ambulatory ECG (Holter), has not been used for 
this purpose. Ambulatory ECG provides, however, a better possibility to assess cardiac 
rhythm in differing circumstances, e.g., at rest, during effort, and – in the case of PD 
patients – during “on” and “off” states. The present study revealed that neither entaca-
pone nor selegiline, administered either separately or together, had any effect on mean 
HR or the occurrence of cardiac arrhythmia during a 24-hour ECG recording (II, IV). This is 
in agreement with the clinical safety data from larger phase III studies on entacapone, in 
which no ECG changes or clinically signifi cant cardiac AEs occurred during 6-month treat-
ment, regardless of the frequent use of selegiline as a co-adjunct therapy (10, 11). Ac-
cording to the prospective 6- to 12-month safety studies in which selegiline was also used 
by about half the patients, the proportion of newly emerging ECG abnormalities between 
the entacapone and placebo arms was comparable (248, 259). In a 3-year open-label 
extension of the phase III Nordic study, no ECG abnormalities occurred with entacapone 
(251). Findings similar to the present results have also been reported with tolcapone as 
add-on therapy to L-dopa. Based on data from 24-h ECG recordings, no change in the 
number of arrhythmic events was observable after 6 months on the drug (281). In an 
open-label study, 2 weeks of tolcapone (mean daily dose of 271 mg) had no effect on the 
24-hour ambulatory HR of eight patients in comparison to matched controls not taking 
the drug (274).
Although several safety studies on entacapone have investigated its effects on exer-
cise hemodynamics in healthy volunteers (16, 17, 271, 272), the present study (IV) is the 
fi rst to investigate the exercise safety of the drug in L-dopa-treated parkinsonian patients. 
Neither ECG nor hemodynamic (BP and HR) responses to maximal exercise changed after 
repeated dosing of entacapone for one week as an add-on to L-dopa. Current fi ndings 
are in accordance with those from studies in healthy volunteers, and are also consistent 
with long-term experience in the cardiovascular and hemodynamic safety of entacapone 
in parkinsonian patients (170, 259). It is also noticeable that all patients participating in 
the present study were on selegiline therapy, which suggests that no exercise-induced 
hemodynamic or cardiac rhythm problems are associated with the concomitant use of 
these two L-dopa adjuncts in PD patients.
6.1.2. Cardiovascular autonomics
In an open-label study by Myllylä et al., a single dose of entacapone had no effect on 
cardiovascular autonomic responses to sympathetic and parasympathetic stimuli (235). 
Prior to the present study (III), however, no double-blind, placebo-controlled trials have 
been performed on the effects of repeated administration of entacapone on cardiovas-
cular autonomic function in PD patients. Such an investigation seemed prudent, because 
many PD patients demonstrate dysfunction of cardiovascular autonomics and because of 
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theoretical safety issues related to inhibition of COMT, due to its role in the function of 
the sympathetic nervous system. In the present study, no clinical evidence of cardiovascu-
lar autonomic dysfunction was sought prior to recruitment. In a post-hoc comparison of 
HR responses with reference values from a healthy Finnish population (287), no clinically 
signifi cant cardiovascular autonomic dysfunction seemed to occur in any patients.
Hemodynamic responses to physicochemical alterations in external/internal milieu are 
due to joint actions of the sympathetic and parasympathetic divisions of the cardiovas-
cular autonomic nervous system. Conventional cardiovascular autonomic refl ex testing 
is a simple and clinically useful method of assessing these responses (285). A battery of 
tests provides the possibility to discriminate between sympathetic and parasympathetic 
dysfunction, and is also useful in the differential diagnostics of parkinsonian syndromes 
(309).
Repeated dosing of entacapone as an adjunct to L-dopa had no effect on any of 
the parameters of cardiovascular autonomic function, such as HR variation during deep 
breathing, the Valsalva maneuver, or orthostatic challenge, results in line with those of 
the previous open-label, single-dose study with comparable methodology (235). Enta-
capone had no signifi cant effect either on BP response during orthostatic testing or on 
frequency of orthostatic hypotension, in accordance with the results from the 6- to 12-
month, double-blind, placebo-controlled phase III studies (10, 11, 248, 259) and the 
3-year open-label study (251), in which neither clinically relevant fi ndings for BP, HR, nor 
any accentuation of orthostatic hypotension was associated with use of entacapone. It 
could be argued that the lack of effect of COMT inhibition on the autonomic parameters 
in the present study is in part due to the predominantly parasympathetic control of these 
responses. However, no potentiation of diastolic BP increase in response to isometric 
effort occurred after entacapone, although this parameter mainly correlates with level 
of sympathetic (noradrenergic) activity. These results therefore suggest that peripheral 
COMT inhibition is devoid of any clinically signifi cant effects on cardiovascular autonomic 
function. The question whether changes in these variables can be detected by using a 
larger number of patients or more accurate and reproducible methods, such as 24-h 
ambulatory ECG with analysis of spectral components of HR variation (52, 310) remains 
unanswered.
Data are scarce on the effects of tolcapone upon cardiovascular autonomic responses. 
In one study, HR variability based on 24-hour ECG did not change after 6 months on the 
drug (281).
Several anti-parkinsonian drugs have been reported to modulate cardiovascular auto-
nomic function: The effects of L-dopa (Section 2.2.3.), in particular, remain controversial 
(18, 43, 61, 166, 308). Although the present results showed an increased frequency of 
orthostatic hypotension after L-dopa (both with and without entacapone) when com-
pared to the overnight withdrawal of the drug, no signifi cant differences occurred in 
mean changes in BP or HR during the orthostatic test. Although both selegiline (61, 166, 
308) and DA agonists (61, 163) have been reported to have effects on cardiovascular 
autonomic function, for instance, aggravation of orthostatic fall in systolic BP (Section 
2.2.3.), responses here seemed not to be biased by these drugs, based on the cross-over 
design of the trial.
6.1.3. Cardiorespiratory exercise performance
Enhanced muscle fatigue, abnormally low peak power (311, 312), reduced metabolic ef-
fi ciency of work on the more affected side (313), ventilatory dysfunction (314–316), and 
cardiovascular autonomic dysfunction (Section 2.1.2.) may all contribute to the impaired 
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cardiovascular competence suggested to occur in PD. Physical fatigue in PD has been 
at least partially related to defi ciency in DA (317). L-dopa has been reported to improve 
ventilatory function (318), exercise endurance, metabolic effi ciency of work (319), and 
physical fatigue in fi nger tapping and force generation (317).
The present study enrolled only those patients with a relatively mild motor disability, 
because patients with advanced disease and signifi cant motor disability are presumed to 
have considerable, if not overwhelming, diffi culties in coping with maximal physical ef-
fort, particularly during the fi rst test after overnight drug withdrawal. No specifi c require-
ments for physical fi tness were set, however, and both sedentary and physically active 
patients were enrolled.
In each case, the maximal level of exercise was evaluated with the use of subjective 
(Borg’s scale), metabolic (RER), and circulatory (age-predicted maximal HR, = 205 – age/2) 
criteria. According to subjective and metabolic criteria, an adequate (maximal) level of 
physical effort was achieved in every case. However, the circulatory criterion of exercise 
maximum was reached by only six (40%) of the patients during every test, whereas seven 
(47%) patients never reached it. That both “blunted” (320, 321) and normal (311, 322) 
HR responses to exercise in comparison to age-predicted maximal HR have been reported 
in parkinsonian patients indicates that the age-predicted maximal HR may not be as valid 
a measure of maximum exercise level in PD patients as it is in healthy humans, possibly 
due to such factors as cardiovascular autonomic incompetence. Because age-predicted 
maximal HR has inherent drawbacks, for instance, measurement error and inter-sub-
ject variability, it is, according to some, an inaccurate indicator maximum exercise level 
(323).
Antiparkinsonian drugs (L-dopa plus selegiline, either with or without entacapone) 
had no infl uence on HR response to exercise when compared to overnight withdrawal of 
treatment. Similar fi ndings of an unchanged HR response between pre- and post L-dopa 
bicycle exercise testing exist (319).
Entacapone did not change the effect of L-dopa on maximum workload; higher values 
for maximum workload were achieved after L-dopa – regardless of entacapone – than 
after overnight withdrawal of antiparkinsonian drugs. This fi nding could be interpreted 
to be in agreement with fi ndings on L-dopa’s improving exercise endurance (319). Other 
factors: placebo and the “training” effect (familiarization with the test procedure) may 
also contribute to such an improvement in work performance.
Entacapone also had no effect on maximum O2 uptake of L-dopa-treated patients. Al-
though a signifi cant increase occurred in maximum O2 uptake after L-dopa plus placebo 
in comparison to control values, no defi nite conclusions on contrasts between control 
and study treatments can be drawn, due to the design of the study (unblinded control, 
fi xed temporal relation of run-in and other test days). The increased maximum O2 uptake 
may have been due to training or other effects, because the maximal workload was also 
higher after study treatments than during control.
In healthy humans, ventilation is not a limiting factor for maximal exercise perform-
ance; instead there exists a ventilatory reserve at peak exercise (defi ned as the difference 
between maximal voluntary and exercise ventilation), also called the breathing reserve. 
In the healthy, this comprises approximately 20 to 40% of maximal voluntary ventilation. 
Low values for breathing reserve are observable in restrictive lung disorders, for instance, 
but also in individuals with extremely high cardiovascular competence. The breathing 
reserve may be abnormally high also when exercise performance is limited by cardiovas-
cular disease. In the calculation of breathing reserve, maximal voluntary ventilation must 
be determined, either by direct measurement or estimation. In neurological disorders, 
indirect estimates may lead to an overestimation of actual maximal voluntary ventilation 
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(324). Such may also be the case in PD, which can demonstrate impaired performance in 
repetitive ventilatory efforts (314, 315), so direct measurement of 15-second maximal vol-
untary ventilation was therefore chosen. Entacapone had no effect on maximum exercise 
ventilation or on the breathing reserve of L-dopa-treated patients, and neither of these 
parameters was altered by L-dopa (with or without entacapone) in comparison to control. 
These results therefore suggest that neither drug changes the ventilatory response to 
maximal exercise.
The effect of work rate was eliminated by comparing cardiorespiratory parameters at 
standard (submaximal) workload, at which O2 uptake is a measure of exercise effi ciency. 
This remained unchanged, irrespective of whether the patients were “off-the-drug” (run-
in) or in the ON-phase after L-dopa. This fi nding somewhat contradicts one report on 
L-dopa’s improving metabolic work effi ciency (319). Overnight drug withdrawal does not, 
however, necessarily represent a true off-state, as L-dopa also has a long-duration effect 
(325). Nor can the dopaminergic effects of longer-acting drugs like DA agonists and 
selegiline be excluded. Entacapone may, at least theoretically, enhance the putative ben-
efi cial effects of L-dopa on exercise performance and effi ciency, although the standard O2 
uptake of L-dopa-treated patients remained unchanged by entacapone.
The standard O2 pulse was slightly but signifi cantly lower after entacapone than after 
placebo. Although the signifi cance of this fi nding remains unknown, among the alterna-
tives, one –  probably the most likely – is the occurrence of a statistically “false-positive” 
fi nding. A less likely one is a true drug effect. The O2 pulse is a compound variable, 
equaling the product of stroke volume and arteriovenous O2 difference. It is unlikely that 
peripheral COMT inhibition would cause any reduction in stroke volume. A decrease in 
the peripheral component of O2 pulse (arteriovenous O2 difference), due perhaps to re-
distribution of blood fl ow or decreased tissue O2 extraction or both, is another possibility. 
Whether or not entacapone can induce such changes remains unresolved. The difference 
in O2 pulse between treatments was minor and not clinically signifi cant.
Ventilatory equivalents for O2 or CO2 are indices of ventilatory effi ciency. Abnormally 
high (=ineffi cient) values for these quotients are observable during hyperventilation and 
in states of pathological mismatch between alveolar ventilation and capillary perfusion. 
Here, that entacapone had no effect on ventilatory equivalents for O2 or CO2 suggests 
that peripheral COMT inhibition does not alter ventilatory response to submaximal work-
load.
In summary, the present fi ndings suggest that in L-dopa-treated PD patients, entaca-
pone – used either in combination with or without selegiline – has no clinically signifi cant 
effect on resting/exercise levels of plasma catecholamines, on hemodynamics, on cardio-
vascular autonomic function, or on cardiorespiratory exercise performance.
6.1.4. Plasma catecholamines
Repeated dosing of entacapone 200 mg with each dose of L-dopa for 2 weeks did not 
change the plasma levels of catecholamines (either NA or DA) in 13 PD patients (I), but 
the metabolic profi le of NA was altered, as demonstrated in the signifi cantly decreased 
plasma level of its COMT-dependent metabolite MHPG. These fi ndings are in agreement 
with previous theories as to the effects of COMT inhibition on methylated catechol me-
tabolites (156), and also with fi ndings in healthy human volunteers (16, 17, 271, 272, 
326). MHPG is formed extraneuronally, either by the sequential actions of MAO and 
COMT on NA or by O-methylation of intraneuronally produced DHPG (327).  The effects 
of acute alterations in neuronal NA release on plasma MHPG are relatively minor, whereas 
the decreased plasma levels of this metabolite have been suggested to accurately refl ect 
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pharmacological inhibition of COMT (326, 328). Findings of unchanged plasma levels of 
catecholamines together with their altered metabolic profi le during COMT inhibition are 
consistent with the presumption that parallel catabolic pathways do compensate for the 
reduced COMT activity. Based on this concept, COMT inhibition results in shunting of 
catecholamine metabolism towards the MAO pathway.
The effects of tolcapone on plasma catecholamine levels may differ from those ob-
served with entacapone. A study of L-dopa-treated PD patients by Rojo et al. demon-
strated a signifi cant (more than six-fold) increase in mean plasma levels of DA, NA, and 
adrenaline after 2-week use of the drug (274). The authors speculated that such differ-
ences in the effects of entacapone and tolcapone on plasma catecholamines may be due 
to the greater potency of tolcapone. In our opinion, however, the data of this particular 
study may have been interpreted erroneously, and the results have not been confi rmed 
in other trials.
In the present study, repeated doses of selegiline 10 mg had no effect on plasma levels 
of DA or NA, nor did it alter the effects of entacapone on plasma MHPG in L-dopa-treated 
parkinsonian patients (I). These results are consistent with this drug’s MAO-B selectivity – 
and therefore its minor contribution to the peripheral catecholamine metabolism – at this 
dose level (152, 329). In peripheral tissues and plasma, no appreciable amounts of MHPG 
seem to be derived from MAO-B-dependent deamination (326, 327). The situation has 
differed with co-inhibition of MAO-A by moclobemide and COMT by entacapone (271). 
In that case, MAO-A seems to be the main contributor to alterations observed in the 
metabolic profi le of NA (mainly decreased plasma MHPG), although plasma levels of free 
catecholamines had remained unchanged.
During strenuous exercise, a marked (at least ten-fold) increase was apparent in plas-
ma levels of free catecholamines such as NA. However, substantial inhibition of peripheral 
COMT by entacapone had no effect on peak exercise concentrations of the plasma NA of 
L-dopa-treated parkinsonian patients (IV). Findings on the effects of both entacapone and 
nitecapone on levels of plasma catechols during exercise performed by healthy human 
volunteers have been in accordance with those results (16, 17, 269-271). The effects of 
tolcapone on plasma catecholamines during exercise have not yet been documented.
6.2. COMT activity and L-dopa pharmacokinetics
After repeated administration of 200 mg of entacapone with each daily dose of L-dopa 
for 2 weeks (I), a highly signifi cant reduction in erythrocyte S-COMT activity occurred, 
measured one hour after the dose, when the inhibitory effect of the drug should be 
at its highest (231). S-COMT activity was reduced by 36 to 38% from baseline (before 
entacapone). Although somewhat higher levels of inhibition at this dose level have ap-
peared in healthy volunteers (231, 242), the present results are in line with other fi ndings 
in PD patients, in which a similar level (33-38%) of inhibition of S-COMT activity occurred 
after entacapone 200 mg (232, 233). COMT activity in erythrocytes was unaffected by 
selegiline, as previously reported (330).
In line with the effective COMT inhibitory activity of entacapone after repeated doses, 
bioavailability (AUC) of L-dopa was much improved (I) without signifi cant changes in its 
absorption kinetics (Cmax and Tmax). These results are in agreement with the majority of 
pharmacokinetic results in healthy human volunteers (236) and PD patients (204, 232-
235). Although some of these were single-dose studies, others have demonstrated that 
the changes in L-dopa pharmacokinetics induced by entacapone remain unaltered from 
day to day during its repeated administration (239, 241).
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The published effects of entacapone on the t1/2 of L-dopa have varied, possibly due 
to differences in properties of study subjects, frequency/duration of sampling, or variable 
absorption after oral doses. No change in the t1/2 of L-dopa at the 200-mg dose level of 
entacapone has been observed by some (236, 239, 242), but fi ndings in parkinsonian 
patients have been more consistent with a signifi cant increase in the t1/2 of L-dopa after 
entacapone (233, 235, 240). This increase has been most prominent after intravenous 
administration of L-dopa (204), because in such circumstances the “true” elimination t1/2 
of the drug (vs. “apparent” t1/2 with oral dosing) can be measured. The present study (I) 
showed no clear increase in the t1/2 of L-dopa caused by entacapone, possibly because 
the study was not primarily designed for pharmacokinetic purposes. Selegiline had no 
effect on the pharmacokinetic parameters of L-dopa, consistent with previous experience 
(331).
In accordance with experience from other repeated-dosing studies (204, 233, 234, 
239), prolonged administration of entacapone caused a highly signifi cant decrease in 
the formation of 3-OMD, the peripheral COMT-dependent metabolite of L-dopa. This 
sustained decrease has also been evident in long-term therapeutic trials (11). The daily 
plasma levels of 3-OMD remained quite stable during repeated assessment, also consist-
ent with earlier results (204, 243) and with the long peripheral half-life of this metabolite 
(199). Due to its stable plasma levels, 3-OMD – unlike highly variable plasma L-dopa and 
COMT activity – is a good measure both of treatment compliance and of the pharmaco-
logical effect of COMT inhibitor therapy.
Consistent with available data (14), the peripheral metabolic profi le of DA was signifi -
cantly affected by concomitant administration of entacapone with L-dopa: plasma levels 
of DOPAC (the MAO-dependent metabolite of DA) were signifi cantly increased, refl ect-
ing a shift in the peripheral metabolism of DA away from COMT and towards MAO-
dependent oxidation. The majority of clinical studies have reported the same for either 
healthy humans (236, 238, 242) or parkinsonian patients (232, 235, 240, 243, 244). The 
increased levels of DOPAC during peripheral COMT inhibition may be the result of an 
increased peripheral decarboxylation of L-dopa to DA and further to DOPAC (14).
Effects of entacapone on plasma HVA (end-metabolite of DA) levels have varied 
more. Some (primarily single-dose) studies have not shown entacapone to alter plasma 
HVA (236, 247). Its plasma levels were, however, signifi cantly reduced by entacapone in 
the current study, consistent with the the majority of clinical trials (232, 234, 238, 240, 
243).
Although experimental animal data on interactions of entacapone and selegiline in 
brain DA metabolism are available (218), clinical studies on the combined effects of these 
drugs on peripheral DA metabolism are lacking. It is clear that DA metabolites derived 
from various sources (brain and peripheral tissues) are mixed in plasma, and their origin 
cannot be traced (192). According to some experiments, however, most plasma HVA 
is extracerebral, derived from MAO-A-dependent deamination of DA in the peripheral 
neurons, and that plasma DOPAC is also primarily derived from cells outside the central 
nervous system. The plasma levels of these metabolites can thus probably not serve as 
indices of central DA (including MAO-B mediated) metabolism (188, 331-333). MAO-B-
selective doses of selegiline should, therefore, have no effects on the metabolic profi le 
of peripheral DA. In line with these ideas, only a negligible effect of selegiline on plasma 
DOPAC has been demonstrable (331, 334). In the present group of PD patients, selegiline 
did not modify the effects of peripheral COMT inhibition on plasma HVA levels, consist-
ent with animal data (332). However, selegiline signifi cantly attenuated the entacapone-
induced increase in plasma DOPAC. Assuming that the majority of plasma DOPAC derives 
from peripheral sources, this fi nding therefore seems to indicate that in the presence of 
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signifi cant peripheral COMT inhibition, selegiline is able to modulate the metabolic pro-
fi le of peripheral DA.
Entacapone demonstrated rapid absorption kinetics, with a Tmax value of approxi-
mately one hour. The pharmacokinetic parameters of the active drug (E-isomer) were 
consistent with those previously seen in healthy volunteers (231, 335). Entacapone also 
has one pharmacologically active metabolite, the Z-isomer. In the present study, the AUC 
of this metabolite accounted for some 6 to 7% of the total plasma AUC of both isomers, 
in accordance with that of other reports (157, 302). That selegiline had no effect on the 
plasma levels of either entacapone or its Z-isomer demonstrates the lack of pharmacoki-
netic interactions between these two drugs.
In summary, entacapone caused a signifi cant reduction in peripheral COMT activity 
and an improvement in L-dopa bioavailability, which is in agreement with available phar-
macokinetic data. Its effects on the metabolites of L-dopa and DA were also consistent 
with those from previous studies. L-dopa t1/2 in this study was not clearly increased. Al-
though selegiline had no effect on the pharmacokinetic parameters of L-dopa, it seemed 
– in the presence of simultaneous COMT inhibition – to alter the metabolic profi le of 
peripheral DA in a manner consistent with its MAO-B inhibitory action. Selegiline had no 
effect on the pharmacokinetics of entacapone.
6.3. Clinical response to L-dopa
Although the effi cacy of entacapone (10, 11, 169, 170, 239) and selegiline (336, 337) 
as adjuncts to L-dopa in PD patients with motor response fl uctuations is established, the 
clinical effects of their combined administration with L-dopa has not been studied sys-
tematically. Data from several long-term studies suggest that entacapone is effi cacious in 
enhancing the clinical effects of L-dopa independent of the extensive usage of selegiline 
as co-adjunct therapy (10, 11, 248, 251).
A wide variety of methods and scales have been applied in the assessment of antipar-
kinsonian drug effi cacy. A composite of various scales for assessment of parkinsonian dis-
ability, disease progression, effi cacy, and complications of antiparkinsonian therapy, the 
UPDRS has good inter-rater reliability and validity for assessing motor response to L-dopa 
in PD patients (79, 338-340). The same applies to the 14-item motor subscale (part III) of 
UPDRS (341), although it has been subject to interference from dyskinesia and dystonia 
(342). The present studies used a slight modifi cation of the motor subscale (234). The 
present defi nition of the onset of motor response (>10% decrease in motor UPDRS from 
baseline) was similar to the ones documented previously (343-345), and also with those 
in other clinical studies on entacapone (232, 239, 243).
In parallel with an increase in L-dopa bioavailability, a signifi cant improvement in daily 
motor disability appeared in one of the studies (I) after the addition of entacapone to 
L-dopa. This is in accordance with results from other phase-II clinical studies with compa-
rable methodology and parameters of clinical effi cacy (234, 243). In the second study (II), 
the differences in mean daily motor scores between control and study treatments were 
non-signifi cant, although adding each study treatment to L-dopa led to some improve-
ment in the other measure of motor disability over the 6-hour time window. Due to 
the unblinded control assessment, however, these secondary statistical comparisons are 
subject to bias.
Selegiline seemed to induce a mild enhancement in the clinical response to enta-
capone plus L-dopa, suggesting an additive therapeutic effect of the combined COMT 
and MAO-B inhibition on L-dopa effi cacy, possibly through the increased entry to and 
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prolonged action of L-dopa in the brain (I). In the second study (II), however, combined 
entacapone and selegiline demonstrated no clinical superiority over either adjunct alone, 
regardless of the effi cacy parameter. These results are therefore also inconclusive. It can 
be speculated that a signifi cantly larger number of patients is required to show any mean-
ingful difference in the effi cacy of these compounds for PD patients on the “optimal” 
(meaning providing the best possible symptom control) therapeutic regimen. An alterna-
tive would be to study patients on sub-optimal L-dopa dosage.
In the present study, duration of clinical response to L-dopa was affected by neither 
separate nor combined administration of entacapone and selegiline, in contrast with the 
other results in PD patients with end-of-dose type motor fl uctuations, in which entaca-
pone has induced a signifi cant increase in ON-time (10, 11, 204, 240, 249). Several expla-
nations for this discrepancy and the lack of effect here on duration of motor response are 
conceivable. One is the small sample size, i.e., lack of power. The other is the character-
istics of the patients; although all had a history of end-of-dose-type motor fl uctuations, 
the presence of these fl uctuations de facto was not objectively verifi ed prior to inclusion. 
A post hoc analysis of UPDRS motor subscores from the second study (II) showed that it 
was conceivable that approximately half the patients demonstrated a rather stable short 
duration response to L-dopa. If motor fl uctuations were actually present in these patients, 
they were rather subtle and not clinically evident. Such a large number of clinically non-
fl uctuating patients could well negate the identifi cation of a potentially positive drug 
response. A need for a more accurate pre-trial evaluation of the state of the disease is 
therefore apparent in clinically mildly affected patients. Finally, there was a tendency for 
a reduced (better) “baseline” motor disability in the mornings after each study treatment 
in comparison to control. This fi nding could be due to placebo effect or true overnight 
extension of dopaminergic effects of the investigated drugs (“sleep benefi t”). This differ-
ence in baseline motor disability seemed to result in an apparent exaggeration of drug 
response in favor of control. The lack of effect of entacapone on time of onset or mag-
nitude of clinical response to L-dopa in the present study is in accordance with both the 
pharmacokinetic data and other clinical experience with the drug (158).
Both entacapone (10, 11, 234, 239, 259) and selegiline (146, 152) may promote dys-
kinesia. In the present study, an aggravation of dyskinesia was therefore anticipated after 
addition of either one or both of these L-dopa adjuncts to patients on an “optimal” an-
tiparkinsonian regimen. As expected, dyskinesia seemed to be most prominent after the 
combination of entacapone and selegiline. In comparison to plain L-dopa (II), a signifi cant 
increase in the mean for daily dyskinesia (AIMS) occurred only after co-administration of 
the two adjuncts. A review by Kaakkola includes reports of this propensity for an increase 
in dyskinesia during entacapone plus selegiline co-therapy with L-dopa (157). Similar 
dyskinesia scores between active study treatments suggest that the co-administration of 
entacapone and selegiline does not result in a clinically signifi cant augmentation of dyski-
nesia compared with the use of either drug alone with L-dopa. L-dopa dosage reductions 
due to dopaminergic AEs were, however, made before assessment of dyskinesia, possibly 
biasing the results by, for instance, diminishing differences between treatments. After 
co-admistration of entacapone and selegiline with L-dopa, the peak dyskinesia score was 
not higher.
In summary, selegiline seemed to slightly enhance the clinical response to entacapone 
plus L-dopa combination therapy in the fi rst study, but not in the second. Several factors 
such as limitations in study power and patient characteristics could partially explain some 
discrepancies. Entacapone had a propensity to lead to increased dyskinesia, most promi-
nently after co-administration with selegiline.
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6.4. Tolerability
The present study indicates that the co-administration of selegiline and entacapone as 
L-dopa adjuncts is safe and well tolerated, in agreement with the clinical safety data from 
several phase II (204, 234, 235, 239, 240) and phase III studies on entacapone (10, 11, 
248, 251, 259), in which a considerable number of patients were on selegiline co-adjunct 
therapy. The co-administration of tolcapone and selegiline as add-on therapy to L-dopa 
has also been reported to be safe and well tolerated (282), although one study showed 
a decrease in tolerability due to diarrhea, nausea, and dizziness after a combination of 
these two drugs for otherwise untreated patients (262).
A tendency appeared toward an increased number of dopa-related AEs after com-
bination of entacapone and selegiline with L-dopa. This was anticipated because the 
dopa-potentiating effects of these two adjuncts are well known (10, 146, 152, 234, 
248), and because the antiparkinsonian therapy was already adjusted to provide the best 
possible symptomatic effect. Nausea, in particular, seemed to occur more frequently dur-
ing co-administration of entacapone and selegiline. Insomnia and sleep-related problems 
seemed to be associated with selegiline, irrespective of entacapone use, in accordance 
with clinical experience with this drug (149). Although selegiline has been suggested to 
infl uence sleep through non-dopaminergic mechanisms (346), the present fi ndings of a 
further increase in frequency of insomnia after a combination of the two L-dopa adjuncts 
suggests that dopaminergic mechanisms are also involved. In a 12-month double-blind 
safety study with 326 patients, however, insomnia occurred at approximately equal fre-
quency during entacapone and placebo, despite the frequent (>80%) use of selegiline in 
both treatment arms (259).
In two of the studies (I, II), L-dopa dosage reduction was necessary in three of 29 pa-
tients after combination of entacapone and selegiline with each other. In each case, this 
was due to emergence of dopaminergic AEs: dystonia or dyskinesia. In the third study 
(III, IV), in which all the patients were on concomitant selegiline therapy, L-dopa dosage 
was reduced after introduction of entacapone in two of 15 patients. In each case, dopa-
related AEs were effectively controlled by these dosage reductions. A re-institution of 
pre-trial L-dopa dosage was required in four of the patients within days after entacapone 
withdrawal because of aggravation of parkinsonian symptoms. This worsening of disabil-
ity upon such withdrawal has been well documented clinically (10, 11, 248, 253, 259).
The two AE-related withdrawals in the studies were considered to be due to excessive 
dopaminergic potentiation by the two L-dopa adjuncts. In these patients, insomnia and 
dizziness were particularly likely to be treatment-related: These are the most common 
treatment-related AEs of entacapone (251), and have also been related to the use of 
selegiline (146, 152).
Dopaminergic therapy is one likely contributor to the sleep disorders in PD; selegiline 
has caused insomnia (149, 347). The effects of L-dopa on sleep are more controversial 
(64, 348-350). Ambulatory activity monitoring (actigraphy) techniques for assessment of 
drug effects on sleep (64, 350), when used in the present study, suggest that combined 
use of entacapone with selegiline in L-dopa-treated PD patients leads to neither deterio-
ration in nor improvement of sleep, making more data necessary for confi rmation.
In summary, the present results suggest an increased tendency for dopa-related AEs 
during the combined use of entacapone and selegiline as L-dopa adjuncts, but this com-
bination of drugs was generally well tolerated, and dopaminergic AEs were, in most 
cases, controlled by reductions in daily dosage of L-dopa.
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7. CONCLUSIONS
The main results of the present study are in line with other clinical experience on the use 
of entacapone as an L-dopa adjunct in parkinsonian patients. They indicate that:
• Co-administration of entacapone plus selegiline with L-dopa is safe and well toler-
ated in PD patients, independent of level of physical activity. No clinically relevant 
drug-drug interactions, such as cardiovascular AEs or potentiation of plasma cat-
echolamine responses occurred.
• Entacapone had no effect on cardiovascular autonomic function.
• Entacapone had no effect on the profi le of cardiorespiratory exercise perform-
ance. 
• The clinical effi cacy of L-dopa may be further improved by combining entaca-
pone and selegiline as L-dopa adjuncts, although clinically signifi cant potentiation 
of dopaminergic AEs, particularly dyskinesia, may also occur. Dopaminergic AEs 
were, in most part, effectively controlled by reducing L-dopa dosage.
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